Methods and pharmaceutical compositions for treatment and prevention of cardiomyopathy associated with Friedel's ataxia
Delivering FXN nucleic acid to the myocardium through AAV vector, solving the problem of insufficient FXN expression in cardiomyopathy caused by Friedreich ataxia, significantly improving myocardial function and prolonging survival, achieving the in vivo in mice and non-human spirits Clinical-related therapeutic effects in leprosy animals.
Patent Information
- Application Number
- CN202380031964.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-13
- Filing Date
- 2023-02-01
- Publication Date
- 2024-12-06
AI Technical Summary
There is currently a lack of effective treatment for cardiomyopathy caused by Friedreich ataxia. The existing technology is difficult to effectively improve the expression of Friedreich ataxia protein (FXN) in the myocardium, leading to myocardial dysfunction and early death.
Adeno-associated virus (AAV) vector carries the nucleic acid sequence encoding FXN, and delivers the AAV vector to the myocardium by intravenous injection, thereby increasing FXN expression in the myocardium to stabilize and improve myocardium associated with Friedreich ataxia. sick.
It significantly improved the FXN expression level in the myocardium, improved myocardial function, extended the survival rate of mouse models, reduced cardiotoxicity, and achieved clinically relevant therapeutic effects in non-human primates.
Smart Images

Figure CN119095626A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to and the benefit of U.S. Provisional Application No. 63 / 305,494, filed on February 1, 2022, and U.S. Provisional Application No. 63 / 341,669, filed on May 13, 2022. The contents of each of these U.S. Provisional Patent Applications are hereby incorporated by reference in their entirety.
[0003] Submit sequence listing as ASCII text file
[0004] The contents of the electronic sequence listing (LEXE_009_001WO_SeqList_ST26.xml; size: 17,703 bytes; and creation date: January 31, 2023) are incorporated herein by reference in their entirety.
[0005] Government funding
[0006] This invention was made with government support under R61HL151355 awarded by the National Institute of Health. The government has certain rights in this invention. Technical Field
[0007] The present invention relates to a method for preventing or treating cardiomyopathy associated with Friedreich's ataxia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (frataxin, FXN). Background Art
[0008] Friedreich's ataxia is an autosomal recessive, progressive, neurodegenerative movement disorder with a typical age of onset between the ages of 10 and 15 years. Clinical manifestations include gait unsteadiness and frequent falls, with progressive effects on movement and coordination.
[0009] Friedreich's ataxia is caused by mutations in the autosomal FXN gene on 9q214. FXN protein is directed to mitochondria (Lupoli 2018; FEBS Lett, 592: 718-27). Ninety-six percent (96%) of FA patients are homozygous for GAA trinucleotide expansion within the first intron, which causes transcriptional silencing through a mechanism involving epigenetic changes, ultimately resulting in reduced levels of FXN messenger RNA (mRNA) compared to normal healthy subjects. Affected individuals have a reduction in FXN protein in all tissues (Puccio 2000; Hum Mol Genet, 9: 887-92). The remaining subjects (4%) are compound heterozygous for GAA expansion and more classic mutations (point mutations, small deletions or insertions) on other alleles, resulting in loss of function of FXN protein (Campuzano 1996; Science, 271: 1423-7).
[0010] The FXN gene consists of seven exons distributed over 85 kb of genomic DNA (Pandolfo 2006; Genetic Instabilities and Neurological Diseases: Chapter 17). The major transcript (1.3 kb) consists of the first five exons located in a 40 kb interval (Campuzano 1996; Pandolfo 2006). Friedreich's ataxia protein encodes a 210 amino acid protein that undergoes a maturation process, typically a nuclear-encoded mitochondrial protein (Miranda 2002; FEBS Lett, 512: 291-7; Puccio 2001; Nat Genet, 27: 181-6). The targeting sequence is contained between amino acids 1-80 and consists of positively charged residues (arginine) in an α-helix (Martelli 2014; Front Pharmacol, 5: 130). Maturation occurs in 2 steps by mitochondrial processing peptidases, first cleavage between positions 41 and 42, which produces an intermediate form of FXN, followed by cleavage starting at amino acid 818, which produces the mature form (Seznec 2004; Hum Mol Genet. 2004; 13: 1017-1024).
[0011] Reduced FXN levels lead to mitochondrial dysfunction with loss of iron-sulfur (Fe-S) cluster enzyme activity (aconitase and respiratory chain complexes I-III), mitochondrial iron accumulation, and increased sensitivity to oxidative stress (Adinolfi 2009; Nat Struct Mol Biol, 16:390-6; Huynen 2001; Hum Mol Genet, 10:2463-8; Muhlenhoff 2002; J Biol Chem, 277:29810-6; Puccio 2001; Schmucker 2011; PLoS One, 6:e16199; Tsai 2010; Biochemistry, 49:9132-9).
[0012] An AAV vector encoding the human FXN gene is disclosed. The AAV vector is infused intravenously. The rh10 capsid is specifically designed for targeted delivery to the myocardium, where it delivers a normal copy of the FXN gene, resulting in increased expression of FXN in cardiomyocytes. It is hypothesized that the vector can stabilize and / or improve cardiomyopathy associated with FA, as measured by cardiopulmonary exercise testing (CPET) and cardiac magnetic resonance imaging (MRI). Summary of the invention
[0013] The present disclosure provides a method for treating or preventing cardiomyopathy associated with Friedreich's ataxia in a subject, the method comprising administering to the subject a therapeutically effective amount of an adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a Friedreich's ataxia protein (FXN) polypeptide or a fragment thereof, wherein the vector is expressed at about 1.0×10 10 gc / kg to about 6.0×10 14 A dose in the range of gc / kg is administered intravenously to the subject.
[0014] The present disclosure provides a method for treating or preventing cardiomyopathy associated with Friedreich's ataxia in a subject, the method comprising administering to the subject a therapeutically effective amount of an adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a Friedreich's ataxia protein (FXN) polypeptide or a fragment thereof, wherein the AAV vector comprises the nucleic acid sequence shown in SEQ ID NO: 9, wherein the vector is expressed at about 1.8×10 11 gc / kg or about 5.6×10 11 A dose of gc / kg was administered intravenously to the subject.
[0015] In some aspects, the AAV vector comprises, in the 5' to 3' direction: a first AAV ITR sequence; an enhancer sequence; a promoter sequence; a chimeric intron; a nucleic acid sequence encoding a Friedreich's ataxia protein (FXN) polypeptide; a polyA sequence; and a second ITR sequence.
[0016] In some aspects, the nucleic acid sequence encoding the Friedreich's ataxia protein (FXN) polypeptide comprises the nucleic acid sequence shown in SEQ ID NO:3. In some aspects, the first ITR sequence comprises the nucleic acid sequence shown in SEQ ID NO:1. In some aspects, the second ITR sequence comprises the nucleic acid sequence shown in SEQ ID NO:2. In some aspects, the enhancer sequence comprises the nucleic acid sequence shown in SEQ ID NO:5. In some aspects, the promoter sequence comprises the nucleic acid sequence shown in SEQ ID NO:6. In some aspects, the polyA sequence comprises the nucleic acid sequence shown in SEQ ID NO:8. In some aspects, the AAV vector comprises the nucleic acid sequence shown in SEQ ID NO:9.
[0017] In some aspects, the AAV vector is packaged as an AAV viral vector comprising an AAV capsid protein. In some aspects, the AAV capsid protein is an AAV1 capsid protein, an AAV2 capsid protein, an AAV4 capsid protein, an AAV5 capsid protein, an AAV6 capsid protein, an AAV7 capsid protein, an AAV8 capsid protein, an AAV9 capsid protein, an AAV10 capsid protein, an AAV11 capsid protein, an AAV12 capsid protein, an AAV13 capsid protein, an AAVPHP.B capsid protein, an AAVrh74 capsid protein, or an AAVrh.10 capsid protein. In some aspects, the AAV capsid protein is an AAVrh10 capsid protein.
[0018] In some aspects, the dose is about 1.8×10 11 gc / kg. In some aspects, the dose is about 5.6×10 11 gc / kg.
[0019] In some aspects, the subject is also administered prednisone. In some aspects, prednisone is administered as follows: once a day at a dose of 40 mg 24 hours before AAV viral vector administration; once a day at a dose of 40 mg from week 1 to week 8 after AAV viral vector administration; once a day at a dose of 30 mg in week 9 after AAV viral vector administration; once a day at a dose of 20 mg in week 10 after AAV viral vector administration; once a day at a dose of 10 mg in week 11 after AAV viral vector administration; once a day at a dose of 5 mg in week 12 after AAV viral vector administration; once a day at a dose of 2.5 mg in week 13 after AAV viral vector administration; and every other day at a dose of 2.5 mg in week 14 after AAV viral vector administration.
[0020] In some aspects, the intravenous administration is performed over about 60 minutes.
[0021] In some aspects, the subject experiences an increase in peak VO2 following AAV vector administration relative to a baseline prior to AAV vector administration.
[0022] In some aspects, peak VO2 is measured in a subject at about 12 weeks, about 24 weeks, about 36 weeks, about 52 weeks, about 18 months, about 2 years, about 3 years, about 4 years, and / or about 5 years after administration of the AAV vector. In some aspects, peak VO2 is measured by cardiopulmonary exercise testing (CPET) using arm ergometry.
[0023] In some aspects, the subject experiences a decrease in left ventricular mass index (LVMi) after AAV vector administration relative to the baseline before AAV vector administration. In some aspects, LVMi is measured at about 12 weeks, about 24 weeks, about 36 weeks, about 52 weeks, about 18 months, about 2 years, about 3 years, about 4 years and / or about 5 years after AAV vector administration. In some aspects, LVMi is measured by cardiac MRI.
[0024] In some aspects, the subject experiences one or more of the following after AAV vector administration relative to a baseline prior to AAV vector administration: a decrease in global longitudinal strain, an increase in stroke volume, an increase in left ventricular ejection fraction (LVEF), and a decrease or stabilization of cardiac fibrosis, as measured by cardiac MRI. In some aspects, the measurements by cardiac MRI occur at about 12 weeks, about 24 weeks, about 36 weeks, about 52 weeks, about 18 months, about 2 years, about 3 years, about 4 years, and / or about 5 years after AAV vector administration.
[0025] In some aspects, the subject experiences a decrease in serum NTproBNP, hsTNT, and CK-MB levels following AAV vector administration relative to a baseline prior to AAV vector administration.
[0026] In some aspects, the subject experiences a reduction in arrhythmias following administration of the AAV vector. In some aspects, arrhythmias are assessed by remote cardiac rhythm monitoring.
[0027] In some aspects, the subject experiences reduced fatigue following AAV vector administration relative to a baseline prior to AAV vector administration, as measured by the Modified Fatigue Impact Scale (MFIS) or the Fatigue Severity Scale (FSS).
[0028] In some aspects, the subject experiences improvement in exertional symptoms (by arm ergometer during CPET) following AAV vector administration relative to a baseline prior to AAV vector administration, as measured by the modified Borg Dyspnea, Borg Rating of Perceived Exhaustion (RPE), and Angina Scale using CPET.
[0029] In some aspects, the subject experiences an increase in FXN expression levels after AAV vector administration relative to a baseline prior to AAV vector administration. In some aspects, the FXN level is myocardial FXN expression level. In some aspects, myocardial FXN expression is measured by cardiac biopsy.
[0030] In some aspects, the subject experiences an increase in FXN expression levels of at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 150%, at least about 200%, at least about 300%, at least about 400%.
[0031] In some aspects, the subject experiences an improvement or stabilization in the Friedreich Ataxia Rating Scale (FARS) or modified Friedreich Ataxia Rating Scale (mFARS) following AAV vector administration relative to a baseline prior to AAV vector administration.
[0032] In some aspects, the subject experiences an improvement or stabilization of the Scale for Assessment and Rating of Ataxia (SARA) following AAV vector administration relative to a baseline prior to AAV vector administration.
[0033] In some aspects, the subject experiences an improvement or stabilization in shortness of breath-daily activities score (SOBDA) following AAV vector administration relative to a baseline prior to AAV vector administration.
[0034] In some aspects, the subject experiences an improvement or stabilization of the Seattle Angina Questionnaire (SAQ) following AAV vector administration relative to a baseline prior to AAV vector administration.
[0035] Any of the above aspects or any other aspect described herein may be combined with any other aspect.
[0036] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those of ordinary skill in the art to which the present disclosure belongs. In the specification, the singular also includes the plural, unless the context clearly indicates otherwise; as an example, the terms "a / an" and "the" should be understood as singular or plural, and the term "or" should be understood as inclusive. For example, "element" means one or more elements.
[0037] Although methods and materials similar or equivalent to the methods and materials described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All disclosures, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. It is not recognized that the references cited herein are prior art of the claimed invention. In the event of a conflict, this specification (including definitions) shall prevail. In addition, these materials, methods and examples are only illustrative and are not intended to be restrictive. Other features and advantages of the present disclosure will be apparent from the following detailed description and claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1A -B shows two graphs depicting the effects of different doses of AAVrh.10FXN on cardiac expression of hFXN in MCK mice. Figure 1A Shown is a line graph depicting dose-dependent cardiac hFXN levels following intravenous administration of three doses. The x-axis depicts the dose administered. The y-axis depicts total cardiac levels of hFXN protein. Figure 1B A bar graph depicting dose-dependent cardiac hFXN levels associated with estimated human levels for conversion of FA homozygotes to heterozygotes is shown. The x-axis depicts dose. The y-axis depicts hFXN protein levels in cardiac tissue. The range of cardiac Friedreich's ataxia protein levels in subjects heterozygous for FA is depicted in the graph as a gray box.
[0039] Figure 2A -B shows two graphs depicting the effect of intravenous administration of AAVrh.10hFXN on body weight in male and female MCK mice. The x-axis depicts the time in days after vector administration. The y-axis depicts body weight in shells. The expected death of MCK mice treated with PBS is depicted by the vertical dashed line. Figure 2A Male mice are shown. Figure 2BFemale mice are shown.
[0040] Figure 3 The results show that the three treatment groups (WT / untreated; MCK / PBS mock-treated; MCK / 1.8×10 12 A series of echocardiographic images taken of mouse heart tissue after administration of 100 gc / kg AAVrh.10 hFXN. The images depict the lateral wall (top) and septal wall (bottom) of the left ventricle from a parasternal short-axis view. The vertical dashed lines measure the relative position of the walls during systole (green) and diastole (red).
[0041] Figure 4A -B shows a depiction of intravenous administration of 1.8×10 12 Two graphs showing improvement in cardiac function in gc / kg AAVrh.10hFXN-treated MCK mice. Figure 4A Cardiac ejection fractions of mice in the three treatment groups are shown. Lines are labeled by treatment group. The x-axis depicts the age of the mice in weeks. The y-axis depicts ejection fraction percentage. Figure 4B The fractional shortening of the heart in the three groups of mice is shown, each labeled next to the corresponding line. The x-axis depicts the age of the mice in weeks. The y-axis depicts the percentage of fractional shortening.
[0042] Figure 5 Survival curves depicting the dose-dependent effects of intravenously administered AAVrh.10hFXN on survival of MCK mice are shown. Mice received three doses of AAVrh.10hFXN, or were mock treated with PBS. Lines are labeled according to treatment. The x-axis depicts the age of the mice in days. The y-axis depicts the survival percentage.
[0043] Figure 6 A schematic diagram of an exemplary model for evaluating the effects of the minimum effective dose and the significantly effective dose as determined in MCK mice in non-human primates (NHPs) is shown. Two doses were administered intravenously and compared with a mock-treated PBS control. Heart tissue was collected 12 weeks after administration and hFXN levels were evaluated.
[0044] Fig. 7A -B shows two diagrams depicting the use of Figure 6 An exemplary model depicted in Figure 2 shows the effects of AAVrh.10hFXN on cardiac expression of hFXN in nonhuman primates. Fig. 7A A bar graph depicting dose-dependent hFXN levels in non-human primate heart tissue is shown. The x-axis depicts the treatment groups. The y-axis depicts hFXN levels. The hFXN levels in the PBS control group are represented by a horizontal dashed line. Figure 7BA bar graph depicting the correlation of hFXN to heterozygous target levels is shown. The x-axis depicts vector dose. The y-axis depicts hFXN levels. The range of cardiac Friedreich's ataxia protein levels in subjects heterozygous for FA is depicted as a gray box in the figure.
[0045] Figures 8A-8C Depicted is an escalating dose study of AAVrh.10hFXN in MCK mice. Fig. 8A is a table depicting the doses of AAVrh.10hFXN administered to mice. Figure 8B is a graph depicting the expression of human Friedreich's ataxia protein in the liver of treated mice following administration of the indicated doses of AAVrh.10hFXN. Figure 8C is a graph depicting the expression of human Friedreich's ataxia protein in the hearts of treated mice following administration of the indicated doses of AAVrh.10hFXN. DETAILED DESCRIPTION
[0046] The present disclosure provides a method for treating or preventing cardiomyopathy associated with Friedreich's ataxia in a subject. In some aspects, the method comprises administering to the subject a therapeutically effective amount of an adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a Friedreich's ataxia protein (FXN) polypeptide or a fragment thereof. In some aspects, the vector is administered in a therapeutically effective amount of 1.0×10 10 gc / kg to about 6.0×10 14 In some aspects, the vector is administered intravenously.
[0047] AAV vectors
[0048] In some aspects, the isolated nucleic acid sequence comprising a nucleic acid sequence encoding Friedreich's ataxia protein (FXN) can be an AAV vector.
[0049] As used herein, the term "adeno-associated virus" or "AAV" refers to a member of a class of viruses associated with the name and belonging to the genus Dependoparvovirus of the family Parvoviridae. Adeno-associated viruses are single-stranded DNA viruses that grow in cells, in which certain functions are provided by co-infected helper viruses. Basic information and reviews of AAV can be found in, for example, Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169-228 and Berns, 1990, Virology, pp. 1743-1764, Raven Press, (New York). It is fully expected that the same principles described in these reviews will be applicable to additional AAV serotypes characterized after the publication date of the reviews, because it is well known that the various serotypes are closely related in structure and function, even at the genetic level. (See, e.g., Blacklowe, 1988, Parvoviruses and Human Disease, pp. 165-174, JR Pattison, ed.; and Rose, Comprehensive Virology 3: 1-61 (1974)). For example, all AAV serotypes apparently exhibit very similar replication properties mediated by homologous rep genes; and all have three related capsid proteins, such as those expressed in AAV2. The degree of relatedness is further indicated by heteroduplex analysis, which shows extensive cross-hybridization between serotypes along the length of the genome; and the presence of similar self-annealing fragments at the ends, which correspond to "inverted terminal repeats" (ITRs). Similar infectivity patterns also indicate that the replication function of each serotype is under similar regulatory control. Multiple serotypes of the virus are known to be suitable for gene delivery; all known serotypes can infect cells from a variety of tissue types. At least 11 sequentially numbered AAV serotypes are known in the art. Non-limiting exemplary serotypes that can be used in the methods disclosed herein include any of the 11 serotypes, such as AAV2, AAV8, AAV9, or variant serotypes, such as AAV-DJ and AAV PHP.B. AAV particles comprise, consist essentially of, or consist of the following three major viral proteins: VP1, VP2, and VP3. In some aspects, AAV refers to serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVPHP.B, AAVrh74, or AAVrh.10.
[0050] Exemplary adeno-associated viruses and recombinant adeno-associated viruses include, but are not limited to, all serotypes (e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVPHP.B, AAVrh74, and AAVrh.10). Exemplary adeno-associated viruses and recombinant adeno-associated viruses include, but are not limited to, self-complementary AAV (scAAV) and AAV hybrids (e.g., AAV2 / 5, AAV-DJ, and AAV-DJ8) containing a genome of one serotype and a capsid of another serotype. Exemplary adeno-associated viruses and recombinant adeno-associated viruses include, but are not limited to, rAAV-LK03, AAV-KP-1 (described in detail in Kerun et al. JCI Insight, 2019; 4(22): e131610), and AAV-NP59 (described in detail in Paulk et al. Molecular Therapy, 2018; 26(1): 289-303).
[0051] AAV is a replication-deficient parvovirus with a single-stranded DNA genome of approximately 4.7 kb in length, including two 145-nucleotide inverted terminal repeats (ITRs). There are multiple AAV serotypes. The nucleotide sequences of the genomes of AAV serotypes are known. For example, the complete genome of AAV-1 is provided in GenBank Accession No. NC_002077; the complete genome of AAV-2 is provided in GenBank Accession No. NC_001401 and Srivastava et al., J. Virol., 45:555-564 (1983); the complete genome of AAV-3 is provided in GenBank Accession No. NC_1829; the complete genome of AAV-4 is provided in GenBank Accession No. NC_001829; the AAV-5 genome is provided in GenBank Accession No. AF085716; AAV- The complete genome of AAV-6 is provided in GenBank Accession No. NC_001862; at least portions of the AAV-7 and AAV-8 genomes are provided in GenBank Accession Nos. AX753246 and AX753249, respectively; the AAV-9 genome is provided in Gao et al., J. Virol., 78:6381-6388 (2004); the AAV-10 genome is provided in Mol. Ther., 13(1):67-76 (2006); and the AAV-11 genome is provided in Virology, 330(2):375-383 (2004). The sequence of the AAV rh.74 genome is provided in U.S. Patent No. 9,434,928. U.S. Patent No. 9,434,928 also provides the sequences of the capsid protein and the self-complementary genome. In one aspect, the AAV genome is a self-complementary genome. Cis-acting sequences that direct viral DNA replication (rep), encapsidation / packaging, and host cell chromosomal integration are contained within the AAV ITR. Three AAV promoters (designated p5, p19, and p40 for their relative map positions) drive expression of two AAV internal open reading frames encoding the rep and cap genes. The two rep promoters (p5 and p19), in combination with differential splicing of a single AAV intron (at nucleotides 2107 and 2227), result in the production of four rep proteins (rep 78, rep 68, rep 52, and rep 40) from the rep gene. Rep proteins have a variety of enzymatic properties that are ultimately responsible for replicating the viral genome.
[0052] The cap gene is expressed by the p40 promoter and encodes three capsid proteins, VP1, VP2 and VP3. Variable splicing and non-shared translation start sites are responsible for producing three related capsid proteins. More specifically, after the single mRNA of each of the VP1, VP2 and VP3 proteins is transcribed, it can be spliced in two different ways: longer or shorter introns can be excised, resulting in the formation of two mRNA sets: 2.3kb and 2.6kb long mRNA sets. Longer introns are usually preferred, so the 2.3kb long mRNA can be called the major splice variant. This form lacks the first AUG codon, and the synthesis of VP1 protein starts from this codon, thereby causing the overall level of VP1 protein synthesis to decrease. The first AUG codon retained in the major splice variant is the start codon of VP3 protein. However, in the same open reading frame, the upstream of this codon is an ACG sequence (encoding threonine), which is surrounded by the optimal Kozak (translation start) environment. As described by Becerra SP et al. (December 1985), this results in lower levels of synthesis of the VP2 protein, which is actually the VP3 protein with an additional N-terminal residue, as is the case with VP1. "Direct mapping of adeno-associated virus capsid proteins B and C: a possible ACG initiation codon". Proceedings of the National Academy of Sciences of the United States of America. 82(23):7919–23, Cassinotti P et al., (November 1988). "Organization of the adeno-associated virus (AAV) capsid gene: mapping of a minor spliced mRNA coding for virus capsid protein 1". Virology. 167(1):176–84, Muralidhar S et al., (January 1994)."Site-directed mutagenesis of adeno-associated virus type 2 structural protein initiation codons: effects on regulation of synthesis and biological activity". Journal of Virology. 68(1): 170–6 and Trempe JP, Carter BJ (September 1988). "Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein". Journal of Virology. 62(9): 3356–63, each of which is incorporated herein by reference. A single consensus polyA site is located at map position 95 of the AAV genome. The life cycle and genetics of AAV are reviewed in Microbiology and Immunology, 158: 97-129 (1992).
[0053] Each VP1 protein contains a VP1 portion, a VP2 portion, and a VP3 portion. The VP1 portion is the N-terminal portion of the VP1 protein, which is unique to the VP1 protein. The VP2 portion is an amino acid sequence present in the VP1 protein, which is also present in the N-terminal portion of the VP2 protein. The VP3 portion and the VP3 protein have the same sequence. The VP3 portion is the C-terminal portion of the VP1 protein, which is common to both the VP1 and VP2 proteins.
[0054] The VP3 protein can be further divided into discrete variable surface regions I-IX (VR-I-IX). Each of the variable surface regions (VRs) can comprise or contain specific amino acid sequences that, alone or in combination with specific amino acid sequences in each of the other VRs, can confer a unique infection phenotype to a particular serotype (e.g., reduced antigenicity, improved transduction, and / or tissue-specific tropism relative to other AAV serotypes), as described in DiMatta et al., "Structural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9", J. Virol., Vol. 86(12): 6947-6958, June 2012, the contents of which are incorporated herein by reference.
[0055] AAV has unique characteristics, which makes it attractive as a vector for delivering exogenous DNA to cells, for example in gene therapy. AAV infection of cells in culture is non-cytopathic, and natural infection in humans and other animals is silent and asymptomatic. Moreover, AAV infects many mammalian cells, allowing the possibility of targeting many different tissues in vivo. In addition, AAV transduces slowly dividing and non-dividing cells, and can basically last the life of these cells as transcriptionally active nuclear episomes (extrachromosomal elements). The AAV proviral genome is inserted as cloned DNA in a plasmid, which makes the construction of recombinant genomes possible. In addition, since the signals for directing AAV replication and genome encapsidation are contained in the ITR of the AAV genome, some or all of the internal approximately 4.3kb genome (encoding replication and structural capsid proteins, rep-cap) can be replaced with exogenous DNA to generate AAV vectors. Rep protein and cap protein can be provided in trans. Another notable feature of AAV is that it is an extremely stable and robust virus. It is easy to withstand the conditions for inactivating adenovirus (56°C to 65°C for several hours), making the refrigeration of AAV less important. AAV can even be lyophilized. Finally, AAV-infected cells do not tolerate repeated infection.
[0056] A number of studies have demonstrated long-term (>1.5 years) recombinant AAV-mediated protein expression in muscle. See, Clark et al., Hum Gene Ther, 8:659-669 (1997); Kessler et al., Proc Nat Acad Sc USA, 93:14082-14087 (1996); and Xiao et al., J Virol, 70:8098-8108 (1996). See also, Chao et al., Mol Ther, 2:619-623 (2000) and Chao et al., Mol Ther, 4:217-222 (2001). In addition, because muscle is highly vascularized, recombinant AAV transduction results in the appearance of transgene products in the systemic circulation after intramuscular injection, as described in Herzog et al., Proc Natl Acad Sci USA, 94:5804-5809 (1997) and Murphy et al., Proc Natl Acad Sci USA, 94:13921-13926 (1997). In addition, Lewis et al., J Virol, 76:8769-8775 (2002) demonstrated that skeletal muscle fibers have the necessary cytokines for correct antibody glycosylation, folding and secretion, indicating that muscle is capable of stably expressing secreted protein therapeutics. The recombinant AAV (rAAV) genome of the present invention comprises, consists essentially of, or consists of a nucleic acid molecule and one or more AAV ITRs flanking the nucleic acid molecule, wherein the nucleic acid molecule comprises a polynucleotide sequence encoding at least one short hairpin RNA (shRNA) molecule against UBE3A-ATS. The generation of pseudotyped rAAV is disclosed in, for example, WO2001083692. Other types of rAAV variants, such as rAAV with capsid mutations, are also contemplated. See, for example, Marsic et al., Molecular Therapy, 22(11):1900-1909 (2014). The nucleotide sequences of the genomes of various AAV serotypes are known in the art.
[0057] As used herein, "AAV vector" refers to a vector comprising, consisting essentially of, or consisting of one or more transgene sequences and one or more AAV inverted terminal repeats (ITRs). In some aspects, the AAV vector contains one or more of the following: an enhancer, a promoter, at least one nucleic acid encoding at least one protein, an intron sequence, and a polyA sequence.
[0058] In some aspects, the invention relates to an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN) for use in treating or preventing cardiomyopathy in a subject in need thereof.
[0059] In some aspects, the invention relates to an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN) for use in treating or preventing cardiomyopathy associated with Friedreich's ataxia in a subject in need thereof.
[0060] In some aspects, the invention relates to an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN) for use in reversing or stabilizing symptoms of cardiomyopathy associated with Friedreich's ataxia in a subject in need thereof.
[0061] In some aspects, the invention relates to an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN) for use in reversing cardiac mitochondrial dysfunction associated with Friedreich's ataxia in a subject in need thereof.
[0062] In some aspects, the invention relates to an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN) for use in improving cardiac mitochondria associated with Friedreich's ataxia in a subject in need thereof.
[0063] In some aspects, the invention relates to an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN) for use in restoring cardiac function in a subject suffering from cardiomyopathy associated with Friedreich's ataxia.
[0064] In some aspects, the invention relates to an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN) for use in improving cardiac function in a subject suffering from cardiomyopathy associated with Friedreich's ataxia.
[0065] In some aspects, the invention relates to an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN) for use in treating cardiomyopathy associated with Friedreich's ataxia in an asymptomatic or presymptomatic subject in need thereof.
[0066] In some aspects, the invention relates to an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN) for use in treating cardiomyopathy associated with Friedreich's ataxia in a symptomatic subject in need thereof.
[0067] In some aspects, the AAV vector used in the methods of the present disclosure comprises, in the 5' to 3' direction, a first AAV ITR sequence; an enhancer sequence, a promoter sequence; a chimeric intron sequence, a nucleic acid sequence encoding Friedreich's ataxia protein; a polyA sequence; and a second ITR sequence.
[0068] In some aspects, the AAV vector encoding Friedreich's ataxia protein of the present disclosure may comprise, consist essentially of, or consist of a nucleic acid sequence that is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% (or any percentage therebetween) identical to SEQ ID NO:9.
[0069] Nucleic acid sequence encoding Friedreich's ataxia protein
[0070] In some aspects, the nucleic acid sequence encoding the Friedreich's ataxia protein (FXN) polypeptide may comprise, consist essentially of, or consist of a nucleic acid sequence having at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% (or any percentage therebetween) identity to SEQ ID NO:3.
[0071] In some aspects, the Friedreich's ataxia (FXN) polypeptide can comprise, consist essentially of, or consist of an amino acid sequence that is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% (or any percentage therebetween) identical to SEQ ID NO:4.
[0072] In some aspects, the present invention provides a nucleic acid sequence comprising SEQ ID NO: 3 or a variant thereof for use in treating cardiomyopathy associated with Friedreich's ataxia.
[0073] Variants include, for example, naturally occurring variants, alternative splicing forms, particularly transcript variants 2 and 3 (accession numbers NM_001161706 and NM_181425) caused by allelic variation (e.g., polymorphism) between individuals. The term variant also includes FXN gene sequences from other sources or organisms. The variant is preferably substantially homologous to SEQ ID NO:3, i.e., exhibits a nucleotide sequence identity of usually at least about 75%, preferably at least about 85%, more preferably at least about 90%, more preferably at least about 95%, 96%, 97%, 98% or 99% with SEQ ID NO:3. Variants of the FXN gene also include nucleic acid sequences that hybridize to the sequence (or its complementary strand) as defined above under stringent hybridization conditions. Typical stringent hybridization conditions include temperatures above 30°C, preferably above 35°C, more preferably above 42°C, and / or a salinity of less than about 500mM, preferably less than 200mM. One skilled in the art can adjust the hybridization conditions by changing the temperature, salinity and / or the concentration of other reagents (such as SDS, SSC, etc.).
[0074] In some aspects, the nucleic acid encoding FXN is a fragment of SEQ ID NO:3.
[0075] In some aspects, a sequence referred to as a mitochondrion-targeting signal or a mitochondrial targeting signal can be added to the FXN coding sequence or variants thereof, including, for example, the FXN coding sequence "81-210." The skilled artisan refers to the sequence referred to as a mitochondrial targeting signal or a mitochondrial targeting signal as an MTS.
[0076] One of ordinary skill in the art can identify MTS sequences within a protein or nucleic acid sequence.
[0077] Most mitochondrial targeting peptides consist of an N-terminal presequence of about 15 to 100 residues, preferably about 20 to 80 residues. They are rich in arginine, leucine, serine and alanine. Mitochondrial presequences show a statistical bias towards positively charged amino acid residues, mainly provided by arginine residues; very few sequences contain negatively charged amino acids. Mitochondrial targeting peptides also enjoy the ability to form amphipathic α-helices.
[0078] For a complete description of methods for identifying MTSs, see: MG Claros, P. Vincens, 1996 (Eur. J. Biochem. 241, 779-786 (1996), "Computational method to predict mitochondrially imported proteins and their targeting sequences"), the contents of which are incorporated herein by reference.
[0079] Inverted terminal repeats
[0080] "Inverted terminal repeats" or "ITRs" refer to regions recognized in the art found at each end of the AAV genome that together act as an origin of DNA replication and as a packaging signal for the virus in cis. The AAV ITRs, together with the AAVrep coding region, provide efficient excision and rescue from nucleotide sequences inserted between the two flanking ITRs, as well as integration of the nucleotide sequences into the genome of mammalian cells. The nucleotide sequences of the AAV ITR regions are known. For AAV-2 sequences, see, for example, Kotin, 1994; Berns, KI "Parvoviridae and their Replication", Fundamental Virology, 2nd edition, (edited by BNFields and DMKnipe). As used herein, "AAV ITRs" do not necessarily comprise wild-type nucleotide sequences, but may be altered, for example, by insertion, deletion or substitution of nucleotides. In addition, AAV ITRs may be derived from any of several AAV serotypes, including but not limited to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, and the like. In addition, the 5' and 3' ITRs flanking the selected nucleotide sequence in the AAV vector do not have to be identical or derived from the same AAV serotype or isolate, as long as they function as intended, i.e., allowing excision and rescue of the sequence of interest from the host cell genome or vector, and allowing the heterologous sequence to be integrated into the recipient cell genome when the AAV Rep gene product is present in the cell. In addition, the AAV ITRs may be derived from any of several AAV serotypes, including but not limited to AAV1, AA2, AAV3, AAV4, AAV5, AAV6, etc. In addition, the 5' and 3' ITRs flanking the selected nucleotide sequence in the AAV expression vector do not have to be identical or derived from the same AAV serotype or isolate, as long as they function as intended, i.e., allowing excision and rescue of the sequence of interest from the host cell genome or vector, and allowing the DNA molecule to be integrated into the recipient cell genome when the AAV Rep gene product is present in the cell.
[0081] In some aspects, the AAV ITR sequence can comprise any AAV ITR sequence known in the art. In some aspects, the AAV ITR sequence can be an AAV1 ITR sequence, an AAV2 ITR sequence, an AAV4 ITR sequence, an AAV5 ITR sequence, an AAV6 ITR sequence, an AAV7 ITR sequence, an AAV8 ITR sequence, an AAV9 ITR sequence, an AAV10 ITR sequence, an AAV11 ITR sequence, an AAV12 ITR sequence, an AAV13 ITR sequence, an AAVrh74 ITR sequence, or an AAVrh10 ITR sequence.
[0082] Thus, in some aspects, the AAV ITR sequence may comprise, consist essentially of, or consist of an AAV1 ITR sequence, an AAV2 ITR sequence, an AAV4 ITR sequence, an AAV5 ITR sequence, an AAV6 ITR sequence, an AAV7 ITR sequence, an AAV8 ITR sequence, an AAV9 ITR sequence, an AAV10 ITR sequence, an AAV11 ITR sequence, an AAV12 ITR sequence, an AAV13 ITR sequence, an AAVrh74 ITR sequence, or an AAVrh10 ITR sequence.
[0083] In some aspects, the rAAV vectors of the present disclosure may comprise, consist essentially of, or consist of an AAV2 ITR sequence. In some aspects, the rAAV vectors of the present disclosure may comprise, consist essentially of, or consist of an AAV2 ITR sequence or a modified AAV2 ITR sequence.
[0084] In some aspects, the first ITR may comprise, consist essentially of, or consist of a nucleic acid sequence having at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% (or any percentage in between) identity to SEQ ID NO: 1, or its complement. In some aspects, the first ITR may comprise, consist essentially of, or consist of a nucleic acid sequence having at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% (or any percentage in between) identity to SEQ ID NO: 2, or its complement.
[0085] In some aspects, the second ITR may comprise, consist essentially of, or consist of a nucleic acid sequence having at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% (or any percentage in between) identity to SEQ ID NO: 1, or its complement. In some aspects, the second ITR may comprise, consist essentially of, or consist of a nucleic acid sequence having at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% (or any percentage in between) identity to SEQ ID NO: 2, or its complement.
[0086] Promoter and enhancer sequences
[0087] As used herein, the terms "promoter" and "promoter sequence" mean a control sequence, which is a region of a polynucleotide sequence in which the initiation and rate of transcription of a coding sequence, such as a gene or transgene, is controlled. For example, a promoter can be constitutive, inducible, repressible, or tissue-specific. A promoter can contain genetic elements to which regulatory proteins and molecules, such as RNA polymerases and transcription factors, can bind.
[0088] The selected nucleotide sequence, such as a nucleotide sequence encoding Friedreich's ataxia protein, is operably linked to control elements that direct its transcription or expression in the subject. Such control elements may include control sequences that are normally associated with the selected gene.
[0089] Alternatively, heterologous control sequences can be used. Useful heterologous control sequences generally include those derived from coding mammalian or viral genes. Examples include, but are not limited to, phosphoglycerate kinase (PKG) promoter, CAG, MCK (muscle creatine kinase), SV40 early promoter, mouse mammary tumor virus LTR promoter; adenovirus major late promoter (AdMLP); herpes simplex virus (HSV) promoter, cytomegalovirus (CMV) promoter such as CMV immediate early promoter region (CMVIE), chicken β-actin (CBA) promoter, Rous sarcoma virus (RSV) promoter, synthetic promoter, hybrid promoter, etc. The promoter can be human or from other species, including from mice. In addition, sequences derived from non-viral genes (such as mouse metallothionein genes) can also be used in the present invention. Such promoter sequences can be commercially available from, for example, Stratagene (SanDiego, CA).
[0090] Examples of heterologous promoters include the CMV promoter.
[0091] Examples of inducible promoters include the DNA response elements for ecdysone, tetracycline, hypoxia, and aufin.
[0092] Enhancer is a regulatory element that increases the expression of a target sequence." Promoter / enhancer " is a polynucleotide containing a sequence that can provide both promoter function and enhancer function. For example, the long terminal repeat sequence of a retrovirus contains both promoter function and enhancer function. Enhancer / promoter can be "endogenous" or "exogenous" or "heterologous". "Endogenous" enhancer / promoter is an enhancer / promoter naturally connected to a given gene in a genome. "Exogenous" or "heterologous" enhancer / promoter is placed in juxtaposition with a gene by gene manipulation (i.e., molecular biotechnology) or synthetic technology, so that the transcription of the gene is guided by the connected enhancer / promoter. Non-limiting examples of enhancers / promoters connected in the methods, compositions and constructs provided herein include the CMV enhancer connected to the CBA promoter. It is understood in the art that enhancers can be operated within a certain distance, regardless of their orientation relative to the endogenous or heterologous promoter position. Thus, it is further understood that an enhancer that operates at a distance from a promoter is therefore "operably linked" to the promoter, regardless of its position in the vector or its orientation relative to the promoter's position.
[0093] As used throughout this disclosure, the term "operably linked" refers to the expression of a gene (i.e., a transgene) that is under the control of a promoter to which it is spatially linked. A promoter can be located 5' (upstream) or 3' (downstream) of a gene under its control. A promoter can be located 5' (upstream) of a gene under its control. The distance between a promoter and a gene can be about the same as the distance between the promoter and the gene it controls in the gene from which the promoter is derived. Variations in the distance between a promoter and a gene can be accommodated without loss of promoter function.
[0094] In some aspects, the enhancer sequence may comprise, consist essentially of, or consist of a human cytomegalovirus (CMV) enhancer sequence. The CMV enhancer sequence may comprise, consist essentially of, or consist of a nucleic acid sequence having at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity (or any percentage therebetween) to SEQ ID NO:5.
[0095] In some aspects, the promoter sequence may comprise, consist essentially of, or consist of a chicken β-actin promoter sequence. The chicken β-actin promoter sequence may comprise, consist essentially of, or consist of a nucleic acid sequence having at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage therebetween) identity to SEQ ID NO: 6.
[0096] Intron sequence
[0097] In some aspects, the intron sequence can include any intron sequence known in the art. In some aspects, the intron sequence can be a chimeric intron sequence. In some aspects, the chimeric intron sequence can include a nucleic acid sequence having at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage therebetween) identity with SEQ ID NO:7, and is essentially composed of it.
[0098] Polyadenylation sequence
[0099] In some aspects, the polyadenylation (polyA) sequence can comprise any polyA sequence known in the art. In some aspects, the polyA sequence can comprise, consist essentially of, or consist of a β-globin polyA sequence. The β-globin polyA sequence can comprise, consist essentially of, or consist of a nucleic acid sequence having at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity (or any percentage therebetween) to SEQ ID NO: 8.
[0100] AAV viral vector
[0101] The AAV vector of the present disclosure can be packaged as an AAV viral vector.
[0102] "AAV viral vector" refers to a viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide AAV vector. Therefore, the production of AAV viral vectors necessarily includes the production of AAV vectors. The term "viral capsid" or "capsid" refers to the protein shell or coating of a viral particle. The capsid plays a role in encapsidating, protecting, transporting and releasing the viral genome into the host cell. The capsid is generally composed of oligomeric structural subunits of a protein ("capsid protein"). As used herein, the term "encapsidation" means encapsidation in a viral capsid. The viral capsid of AAV is composed of a mixture of three viral capsid proteins: VP1, VP2 and VP3.
[0103] AAV viral vectors useful in the practice of the present invention can be constructed using methods well known in the field of molecular biology. Generally, AAV viral vectors carrying transgenes are assembled from polynucleotides encoding transgenes, appropriate regulatory elements, and elements necessary to produce viral proteins that mediate cell transduction.
[0104] The term "gene transfer" or "gene delivery" refers to a method or system for reliably inserting foreign DNA into a host cell. Such methods can result in transient expression of non-integrated transferred DNA, extrachromosomal replication and expression of transferred replicons (e.g., episomes), or integration of transferred genetic material into the genomic DNA of the host cell.
[0105] Examples of viral vectors include, but are not limited to, adenoviral, retroviral, lentiviral, herpes viral, and adeno-associated viral (AAV) vectors.
[0106] Such recombinant viruses can be produced by techniques known in the art, such as by transfecting packaging cells or by transient transfection with helper plasmids or viruses. Typical examples of viral packaging cells include PA317 cells, PsiCRIP cells, GPenv+ cells, 293 cells, etc. Detailed protocols for producing such replication-defective recombinant viruses can be found in, for example, WO95 / 14785, WO96 / 22378, US5,882,877, US6,013,516, US4,861,719, US5,278,056, and WO94 / 19478.
[0107] In one embodiment, an adeno-associated virus (AAV) vector is employed.
[0108] In other embodiments, the AAV vector is AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVPHP.B, AAVrh74, AAVrh.10, or any other serotype of AAV known in the art that can infect humans, monkeys, or other species.
[0109] In an exemplary embodiment, the AAV vector is an AAVrh10 vector.
[0110] "AAV vector" means a vector derived from an adeno-associated virus serotype, including but not limited to AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVPHP.B, AAVrh74 or AAVrh.10. The AAV vector may have one or more AAV wild-type genes that are completely or partially deleted, preferably rep and / or cap genes, but retain functional flanking ITR sequences. Functional ITR sequences are essential for the rescue, replication and packaging of AAV virions. Therefore, the AAV vector is defined herein as comprising at least those sequences required for viral replication and packaging (e.g., functional ITR) in cis. ITR is not necessarily a wild-type nucleotide sequence, and can be, for example, changed by insertion, deletion or replacement of nucleotides, as long as the sequence provides functional rescue, replication and packaging. AAV expression vectors are constructed using known techniques to provide at least control elements as operably linked components in the direction of transcription, including a transcription initiation region, a DNA of interest (ie, FXN gene), and a transcription termination region.
[0111] The control elements are selected to be functional in mammalian cells. The resulting construct containing the operably linked components is combined with functional AAV ITR sequences (5' and 3').
[0112] Particularly preferred are vectors derived from AAV serotypes that have tropism and high transduction efficiency for cells of the mammalian myocardium, particularly cardiomyocytes and cardiomyocyte progenitor cells. A review and comparison of the transduction efficiency of different serotypes is provided in Cearley CN et al., 2008. In other non-limiting examples, preferred vectors include vectors derived from any serotype such as AAV1, AAV2, AAV3, AAV4, AA5, AAV6, AAV7, AAV8, AAV9 or AAVrh10, which have also been shown to transduce cardiomyocytes.
[0113] AAV expression vectors carrying a DNA molecule of interest bound by AAV ITRs can be constructed by inserting the selected sequence directly into the AAV genome from which the major AAV open reading frame ("ORF") has been excised. Other portions of the AAV genome may also be deleted as long as sufficient ITR portions are retained to allow replication and packaging functions. Such constructs can be designed using techniques well known in the art. See, e.g., U.S. Pat. Nos. 5,173,414 and 5,139,941; International Publication Nos. WO 92 / 01070 (published on January 23, 1992) and WO 93 / 03769 (published on March 4, 1993); Lebkowski et al., 1988; Vincent et al., 1990; Carter, 1992; Muzyczka, 1992; Kotin, 1994; Shelling and Smith, 1994; and Zhou et al., 1994. Alternatively, the AAV ITR can be excised from the viral genome or from an AAV vector containing the viral genome and fused to the 5' and 3' of a selected nucleic acid construct present in another vector using standard ligation techniques. AAV vectors containing ITRs have been described in, for example, U.S. Patent No. 5,139,941. In particular, several AAV vectors with accession numbers 53222, 53223, 53224, 53225 and 53226 available from the American Type Culture Collection ("ATCC") are described. In addition, chimeric genes can be produced synthetically to include AAV ITR sequences arranged at 5' and 3' of one or more selected nucleic acid sequences. Preferred codons for expressing chimeric gene sequences in mammalian CNS cells can be used. The complete chimeric sequence is assembled from overlapping oligonucleotides prepared by standard methods. See, for example, Edge, 1981; Nambair et al., 1984; Jay et al., 1984. To produce AAV virions, the AAV expression vector is introduced into a suitable host cell using known techniques (such as by transfection). Many transfection techniques are generally known in the art. See, for example, Graham et al., 1973; Sambrook et al. (1989) Molecular Cloning, alaboratory manual, Cold Spring Harbor Laboratories, New York; Davis et al. (1986) Basic Methods in Molecular Biology, Elsevier; and Chu et al., 1981.Particularly suitable transfection methods include calcium phosphate coprecipitation (Graham et al., 1973), direct microinjection into cultured cells (Capecchi, 1980), electroporation (Shigekawa et al., 1988), liposome-mediated gene transfer (Mannino et al., 1988), lipid-mediated transduction (Felgner et al., 1987), and nucleic acid delivery using high-speed microprojectile bombardment (Klein et al., 1987).
[0114] For example, a preferred viral vector, such as AAVrh10, comprises, in addition to the nucleic acid sequence encoding FXN, an AAV vector backbone with ITRs derived from AAV2, a promoter, such as the mouse PGK (phosphoglycerate kinase) gene or the cytomegalovirus / β-actin hybrid promoter (CAG), which consists of an enhancer from the cytomegalovirus immediate gene, a promoter from the chicken β-actin gene, a splice donor and intron, a splice acceptor from rabbit β-globin, or any promoter (such as PGK, CAG, MCK).
[0115] The AAV viral vector of the present disclosure comprises: i) the AAV vector described herein; and ii) an AAV capsid protein.
[0116] In some aspects, the AAV capsid protein can be any AAV capsid protein. In some aspects, the AAV capsid protein is an AAV1 capsid protein, an AAV2 capsid protein, an AAV4 capsid protein, an AAV5 capsid protein, an AAV6 capsid protein, an AAV7 capsid protein, an AAV8 capsid protein, an AAV9 capsid protein, an AAV10 capsid protein, an AAV11 capsid protein, an AAV12 capsid protein, an AAV13 capsid protein, an AAVPHP.B capsid protein, an AAVrh74 capsid protein, or an AAVrh.10 capsid protein. In some aspects, the AAV capsid protein is an AAVrh.10 capsid protein.
[0117] Treatment
[0118] The first object of the present invention relates to a method for treating or preventing cardiomyopathy in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an AAV vector comprising a nucleic acid sequence encoding a Friedreich's ataxia protein (FXN) polypeptide or a fragment thereof.
[0119] In a particular embodiment, the cardiomyopathy can be dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, or ischemic cardiomyopathy.
[0120] In another specific embodiment, the cardiomyopathy may be a cardiomyopathy due to insufficient fat oxidation, including but not limited to primary carnitine deficiency, LCHAD, translocase, VLCAD.
[0121] In another specific embodiment, the cardiomyopathy can be a cardiomyopathy associated with Friedreich's ataxia.
[0122] In a particular embodiment, the gene encoded by the nucleic acid sequence in the AAV vector can be a nuclear gene encoding a subunit of the pyruvate dehydrogenase complex, a nuclear gene or a mitochondrial gene encoding a subunit of complex I, III, IV or V involved in oxidative phosphorylation; a mitochondrial gene encoding a transfer RNA, a gene involved in mitochondrial biogenesis (such as SIRT1), a gene involved in mitochondrial fusion (such as OPA1), a gene involved in mitochondrial fission (such as FIS1), or a gene involved in fatty acid oxidation (such as very long chain-specific acyl-CoA dehydrogenase).
[0123] In a specific embodiment, the gene encoded by the nucleic acid sequence in the AAV vector is the Friedreich's ataxia protein (FXN) gene.
[0124] As used herein, the term "preventing" or "prevention" in its broadest sense refers to preventing a disease or disorder from occurring in a subject who has not yet been diagnosed with the disease or disorder or does not have any clinical symptoms.
[0125] As used herein, the terms "treating" or "treatment", as used herein, mean reversing, alleviating, or inhibiting the progression of the disorder or condition to which such terms apply, or one or more symptoms of such disorder or condition. "Therapeutically effective amount" refers to the minimum amount of an active agent necessary to confer a therapeutic benefit on a subject. For example, a "therapeutically effective amount" for a patient is an amount that induces, ameliorates, stabilizes, slows the progression of, or otherwise causes an improvement in a pathological symptom, disease progression, or physiological condition associated with or resistant to death from a disorder.
[0126] As used herein, the term "subject" refers to a mammal, such as a rodent, a feline, a canine, and a primate. In some aspects, the subject according to the present invention is a human. In the context of the present invention, a "subject in need" refers to a subject, preferably a human, and more particularly a subject suffering from a cardiomyopathy associated with Friedreich's ataxia. Subjects suffering from a cardiomyopathy associated with Friedreich's ataxia present with some cardiac symptoms, which may be, but are not limited to, a reduced ejection fraction, an increase in ventricular mass, or cardiac hypertrophy. Therefore, the method of the present invention will be very suitable for treating subjects suffering from such a disease (Friedreich's ataxia) presenting such symptoms.
[0127] As used herein, the term "gene" refers to a polynucleotide containing at least one open reading frame that is capable of encoding a specific polypeptide or protein after transcription and translation.
[0128] As used herein, the term "coding sequence", "sequence encoding a specific protein" or "coding nucleic acid" refers to a nucleic acid sequence that is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. The coding sequence may include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and even synthetic DNA sequences.
[0129] In a specific embodiment, the present invention relates to a method for preventing or treating cardiomyopathy associated with Friedreich's ataxia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN).
[0130] In a specific embodiment, the present invention relates to a method for treating cardiomyopathy associated with Friedreich's ataxia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN).
[0131] In a specific embodiment, the present invention is directed to a method for reversing or stabilizing symptoms of cardiomyopathy associated with Friedreich's ataxia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN).
[0132] As used herein, the term "reversing the symptoms of cardiomyopathy associated with Friedreich's ataxia" means restoring cardiac function by, for example, improving ejection fraction and / or reducing ventricular mass in a subject in need thereof.
[0133] In a specific embodiment, the present invention relates to a method for reversing cardiac mitochondrial dysfunction associated with Friedreich's ataxia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN).
[0134] In a specific embodiment, the present invention relates to a method for improving cardiac mitochondria associated with Friedreich's ataxia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN).
[0135] In a specific embodiment, the present invention relates to a method for restoring cardiac function in a subject suffering from cardiomyopathy associated with Friedreich's ataxia, the method comprising administering to the subject a therapeutically effective amount of an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN).
[0136] In a specific embodiment, the present invention relates to a method for improving cardiac function in a subject suffering from cardiomyopathy associated with Friedreich's ataxia, the method comprising administering to the subject a therapeutically effective amount of an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN).
[0137] In a specific embodiment, the present invention relates to a method for treating cardiomyopathy associated with Friedreich's ataxia in an asymptomatic or presymptomatic subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN).
[0138] In another specific embodiment, the present invention is directed to a method for treating cardiomyopathy associated with Friedreich's ataxia in a symptomatic subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN).
[0139] As used herein, the term "asymptomatic" or "presymptomatic" refers to a subject who has the disease (Friedreich's ataxia) as defined by genetic diagnosis (for review, see Lynch DR et al., Arch Neurol. 2002; 59:743-747) but has no detectable clinical cardiac symptoms.
[0140] As used herein, the term symptomatic refers to a subject who suffers from the disease as defined by genetic diagnosis (Friedreich's ataxia) and has the presence of cardiac symptoms (cardiac hypertrophy, fibrosis, decreased myocardial perfusion reserve index, impaired myocardial or skeletal muscle mitochondrial respiratory chain function, subclinical cardiomyopathy, supraventricular arrhythmias, heart failure, systolic left ventricular dysfunction, fatigue, ...).
[0141] The FXN gene encodes the protein Friedreich's ataxia. Friedreich's ataxia is a protein that localizes to mitochondria. Friedreich's ataxia is involved in the assembly of iron-sulfur clusters by regulating iron entry and the activity of cysteine desulfurase.
[0142] In some aspects, the invention relates to a method for preventing or treating a disease associated with Friedreich's ataxia deficiency in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an AAV vector comprising a nucleic acid encoding Friedreich's ataxia.
[0143] In some aspects, the present invention relates to a method for preventing or treating cardiomyopathy in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an AAV vector comprising a nucleic acid encoding Friedreich's ataxia protein (FXN).
[0144] In some aspects, the subject experiences an increase in peak oxygen consumption (peak VO2) after AAV vector administration relative to the baseline before AAV vector administration. In some aspects, the peak VO2 in the subject is measured at about 12 weeks, about 24 weeks, about 36 weeks, about 52 weeks, about 18 months, about 2 years, about 3 years, about 4 years, and / or about 5 years after AAV vector administration. In some aspects, VO2 is a measure that depicts the rate of oxygen consumption. In some aspects, VO2 is the volume of oxygen consumed per unit time.
[0145] In some aspects, peak VO2 is measured by cardiopulmonary exercise testing (CPET) using arm ergometer.
[0146] In some aspects, the subject experiences a decrease in left ventricular mass index (LVMi) following AAV vector administration relative to a baseline prior to AAV vector administration.
[0147] In some aspects, LVMi is measured at about 12 weeks, about 24 weeks, about 36 weeks, about 52 weeks, about 18 months, about 2 years, about 3 years, about 4 years, and / or about 5 years after AAV vector administration. In some aspects, LVMi is measured by cardiac MRI.
[0148] In some aspects, the subject experiences one or more of the following following AAV vector administration relative to a baseline prior to AAV vector administration: a decrease in global longitudinal strain, an increase in stroke volume, an increase in left ventricular ejection fraction (LVEF), and a decrease or stabilization of cardiac fibrosis as measured by cardiac MRI.
[0149] In some aspects, the measurements by cardiac MRI occur at about 12 weeks, about 24 weeks, about 36 weeks, about 52 weeks, about 18 months, about 2 years, about 3 years, about 4 years, and / or about 5 years after administration of the AAV vector.
[0150] In some aspects, the subject experiences a decrease in serum NTproBNP, hsTNT, and / or CK-MB levels following AAV vector administration relative to a baseline prior to AAV vector administration.
[0151] In some aspects, the subject experiences a reduction in arrhythmias following AAV vector administration relative to a baseline prior to AAV vector administration. In some aspects, the subject experiences a reduced incidence of arrhythmias following AAV vector administration relative to a baseline prior to AAV vector administration.
[0152] In some aspects, arrhythmias are evaluated via remote cardiac rhythm monitoring.
[0153] In some aspects, the subject experiences reduced fatigue following AAV vector administration relative to a baseline prior to AAV vector administration, as measured by the Modified Fatigue Impact Scale (MFIS) or the Fatigue Severity Scale (FSS).
[0154] In some aspects, the subject experiences improvement in exertional symptoms (by arm ergometer during CPET) following AAV vector administration relative to a baseline prior to AAV vector administration, as measured by the modified Borg dyspnea, Borg Rating of Perceived Exhaustion (RPE), and Angina Scale using CPET.
[0155] It is well known that Friedreich's ataxia heterozygotes (those individuals with one normal FXN allele) have no clinical manifestations of FA. FA homozygotes (individuals with two abnormal and / or mutated FXN alleles) experience symptoms. Analysis of the average FXN levels in autopsy samples of the hearts of 5 healthy individuals confirmed that the normal level of FXN in the human heart is 59±5ng / mg protein. It is estimated that the average cardiac Friedreich's ataxia protein level in FA homozygotes is about 9.4ng / mg. Further, it is well known that FA heterozygotes have 30%-80% of the normal level of FXN (19-50ng / mg Friedreich's ataxia protein) relative to healthy individuals. Without wishing to be bound by theory, it is reasonable to expect that increasing the level of Friedreich's ataxia protein in FA homozygotes to a level close to or above the level of FA heterozygotes or healthy individuals will result in improved symptom experience in FA homozygotes. In some aspects, following administration of an AAV vector of a vector encoding FXN disclosed herein, the patient experiences increased expression of Friedreich's ataxia protein. In some aspects, the increased expression of Friedreich's ataxia protein occurs in the heart.
[0156] In some aspects, the amount of Friedreich's ataxia protein in the heart of the subject increases by about 1 ng / mg, about 2 ng / mg, about 3 ng / mg, about 4 ng / mg, about 5 ng / mg, about 6 ng / mg, about 7 ng / mg, about 8 ng / mg, about 9 ng / mg, about 10 ng / mg, about 11 ng / mg, about 12 ng / mg, about 13 ng / mg, about 14 ng / mg, about 15 ng / mg, about 20 ng / mg, about 25 ng / mg, about 30 ng / mg, about 35 ng / mg, about 40 ng / mg, about 45 ng / mg, about 50 ng / mg, about 60 ng / mg, about 70 ng / mg, about 80 ng / mg, about 90 ng / mg, about 100 ng / mg, about 200 ng / mg, about 300 ng / mg, about 400 ng / mg, or about 500 ng / mg after administration of the AAV vector relative to a baseline before administration.
[0157] In some aspects, the subject experiences an increase in FXN expression levels after AAV vector administration relative to the baseline before AAV vector administration. In some aspects, an increase in FXN levels refers to an increase in the mRNA level of FXN. In some aspects, an increase in FXN levels refers to an increase in Friedreich's ataxia protein (FXN) protein levels.
[0158] In some aspects, the FXN level is the myocardial FXN expression level. In some aspects, myocardial FXN expression is measured by cardiac biopsy.
[0159] In some aspects, the subject experiences an increase in FXN expression levels of at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 150%, at least about 200%, at least about 300%, at least about 400%, or at least about 500%, relative to a baseline prior to administration of the AAV vector.
[0160] In some aspects, the subject experiences an improvement or stabilization in the Friedreich Ataxia Rating Scale (FARS) or modified Friedreich Ataxia Rating Scale (mFARS) following AAV vector administration relative to a baseline prior to AAV vector administration.
[0161] In some aspects, the subject experiences an improvement or stabilization of the Scale for Assessment and Rating of Ataxia (SARA) following AAV vector administration relative to a baseline prior to AAV vector administration.
[0162] In some aspects, the subject experiences an improvement or stabilization in shortness of breath-daily activities score (SOBDA) following AAV vector administration relative to a baseline prior to AAV vector administration.
[0163] In some aspects, the subject experiences an improvement or stabilization of the Seattle Angina Questionnaire (SAQ) following AAV vector administration relative to a baseline prior to AAV vector administration.
[0164] Delivery of vector
[0165] Provided herein is a method for treating cardiomyopathy associated with Friedreich's ataxia in a subject, the method comprising: (a) providing an AAV vector as defined above, comprising a nucleic acid sequence encoding a Friedreich's ataxia protein (FXN) polypeptide or a fragment thereof; and (b) delivering the AAV vector to a subject in need thereof, whereby FXN is expressed by the transduced cells at therapeutically effective levels.
[0166] The preferred dosage and regimen can be determined by a physician and depends on the subject's age, sex, weight, and stage of disease.
[0167] In some aspects, the AAV vector is administered intravenously (IV) to the subject. In some aspects, the IV infusion occurs over at least about 5 minutes, at least about 10 minutes, at least about 20 minutes, at least about 30 minutes, at least about 40 minutes, at least about 50 minutes, at least about 60 minutes, at least about 70 minutes, at least about 80 minutes, at least about 90 minutes, at least about 100 minutes, at least about 110 minutes, or at least about 120 minutes. In some aspects, the IV infusion occurs within 60 minutes.
[0168] In some aspects, the AAV vector of the present disclosure is administered to a subject at a therapeutically effective dose. In some aspects, the dose is between about 1.0×10 10 genome copies (gc) / kilogram (kg) (gc / kg) to about 9.9×10 14 In some aspects, the dosage is between about 1.0×10 10 gc / kg to about 6.0×10 14 In some aspects, the dosage is between about 1.0×10 10 gc / kg to about 6.0×10 13 In some aspects, the dosage is between about 1.0×10 10 gc / kg is about 9.9×10 13 In some aspects, the dosage is between about 1.0×10 10 gc / kg is about 9.9×10 12In some aspects, the dosage is between about 1.0×10 10 gc / kg is about 9.9×10 11 In some aspects, the dosage is between about 1.0×10 11 gc / kg is about 9.9×10 14 In some aspects, the dosage is between about 1.0×10 12 gc / kg is about 9.9×10 14 In some aspects, the dosage is between about 1.0×10 13 gc / kg is about 9.9×10 14 In some aspects, the dosage is between about 1.0×10 14 gc / kg is about 9.9×10 14 Between gc / kg.
[0169] In some aspects, the dose is about 1.0×10 10 gc / kg, about 1.1×10 10 gc / kg, about 1.2×10 10 gc / kg, about 1.3×10 10 gc / kg, about 1.4×10 10 gc / kg, about 1.5×10 10 gc / kg, about 1.6×10 10 gc / kg, about 1.7×10 10 gc / kg, about 1.8×10 10 gc / kg, about 1.9×10 10 gc / kg, about 2.0×10 10 gc / kg, about 2.1×10 10 gc / kg, about 2.2×10 10 gc / kg, about 2.3×10 10 gc / kg, about 2.4×10 10 gc / kg, about 2.5×10 10 gc / kg, about 2.6×10 10 gc / kg, about 2.7×10 10 gc / kg, about 2.8×10 10 gc / kg, about 2.9×10 10 gc / kg, about 3.0×10 10 gc / kg, about 3.1×10 10 gc / kg, about 3.2×10 10 gc / kg, about 3.3×10 10 gc / kg, about 3.4×1010 gc / kg, about 3.5×10 10 gc / kg, about 3.6×10 10 gc / kg, about 3.7×10 10 gc / kg, about 3.8×10 10 gc / kg, about 3.9×10 10 gc / kg, about 4.0×10 10 gc / kg, about 4.1×10 10 gc / kg, about 4.2×10 10 gc / kg, about 4.3×10 10 gc / kg, about 4.4×10 10 gc / kg, about 4.5×10 10 gc / kg, about 4.6×10 10 gc / kg, about 4.7×10 10 gc / kg, about 4.8×10 10 gc / kg, about 4.9×10 10 gc / kg, about 5.0×10 10 gc / kg, about 5.1×10 10 gc / kg, about 5.2×10 10 gc / kg, about 5.3×10 10 gc / kg, about 5.4×10 10 gc / kg, about 5.5×10 10 gc / kg, about 5.6×10 10 gc / kg, about 5.7×10 10 gc / kg, about 5.8×10 10 gc / kg, about 5.9×10 10 gc / kg, about 6.0×10 10 gc / kg, about 6.1×10 10 gc / kg, about 6.2×10 10 gc / kg, about 6.3×10 10 gc / kg, about 6.4×10 10 gc / kg, about 6.5×10 10 gc / kg, about 6.6×10 10 gc / kg, about 6.7×10 10 gc / kg, about 6.8×10 10 gc / kg, about 6.9×10 10 gc / kg, about 7.0×10 10 gc / kg, about 7.1×10 10 gc / kg, about 7.2×10 10gc / kg, about 7.3×10 10 gc / kg, about 7.4×10 10 gc / kg, about 7.5×10 10 gc / kg, about 7.6×10 10 gc / kg, about 7.7×10 10 gc / kg, about 7.8×10 10 gc / kg, about 7.9×10 10 gc / kg, about 8.0×10 10 gc / kg, about 8.1×10 10 gc / kg, about 8.2×10 10 gc / kg, about 8.3×10 10 gc / kg, about 8.4×10 10 gc / kg, about 8.5×10 10 gc / kg, about 8.6×10 10 gc / kg, about 8.7×10 10 gc / kg, about 8.8×10 10 gc / kg, about 8.9×10 10 gc / kg, about 9.0×10 10 gc / kg, about 9.1×10 10 gc / kg, about 9.2×10 10 gc / kg, about 9.3×10 10 gc / kg, about 9.4×10 10 gc / kg, about 9.5×10 10 gc / kg, about 9.6×10 10 gc / kg, about 9.7×10 10 gc / kg, about 9.8×10 10 gc / kg or about 9.9×10 10 gc / kg.
[0170] In some aspects, the dose is about 1.0×10 11 gc / kg, about 1.1×10 11 gc / kg, about 1.2×10 11 gc / kg, about 1.3×10 11 gc / kg, about 1.4×10 11 gc / kg, about 1.5×10 11 gc / kg, about 1.6×10 11 gc / kg, about 1.7×10 11 gc / kg, about 1.8×10 11 gc / kg, about 1.9×10 11gc / kg, about 2.0×10 11 gc / kg, about 2.1×10 11 gc / kg, about 2.2×10 11 gc / kg, about 2.3×10 11 gc / kg, about 2.4×10 11 gc / kg, about 2.5×10 11 gc / kg, about 2.6×10 11 gc / kg, about 2.7×10 11 gc / kg, about 2.8×10 11 gc / kg, about 2.9×10 11 gc / kg, about 3.0×10 11 gc / kg, about 3.1×10 11 gc / kg, about 3.2×10 11 gc / kg, about 3.3×10 11 gc / kg, about 3.4×10 11 gc / kg, about 3.5×10 11 gc / kg, about 3.6×10 11 gc / kg, about 3.7×10 11 gc / kg, about 3.8×10 11 gc / kg, about 3.9×10 11 gc / kg, about 4.0×10 11 gc / kg, about 4.1×10 11 gc / kg, about 4.2×10 11 gc / kg, about 4.3×10 11 gc / kg, about 4.4×10 11 gc / kg, about 4.5×10 11 gc / kg, about 4.6×10 11 gc / kg, about 4.7×10 11 gc / kg, about 4.8×10 11 gc / kg, about 4.9×10 11 gc / kg, about 5.0×10 11 gc / kg, about 5.1×10 11 gc / kg, about 5.2×10 11 gc / kg, about 5.3×10 11 gc / kg, about 5.4×10 11 gc / kg, about 5.5×10 11 gc / kg, about 5.6×10 11 gc / kg, about 5.7×10 11 gc / kg, about 5.8×1011 gc / kg, about 5.9×10 11 gc / kg, about 6.0×10 11 gc / kg, about 6.1×10 11 gc / kg, about 6.2×10 11 gc / kg, about 6.3×10 11 gc / kg, about 6.4×10 11 gc / kg, about 6.5×10 11 gc / kg, about 6.6×10 11 gc / kg, about 6.7×10 11 gc / kg, about 6.8×10 11 gc / kg, about 6.9×10 11 gc / kg, about 7.0×10 11 gc / kg, about 7.1×10 11 gc / kg, about 7.2×10 11 gc / kg, about 7.3×10 11 gc / kg, about 7.4×10 11 gc / kg, about 7.5×10 11 gc / kg, about 7.6×10 11 gc / kg, about 7.7×10 11 gc / kg, about 7.8×10 11 gc / kg, about 7.9×10 11 gc / kg, about 8.0×10 11 gc / kg, about 8.1×10 11 gc / kg, about 8.2×10 11 gc / kg, about 8.3×10 11 gc / kg, about 8.4×10 11 gc / kg, about 8.5×10 11 gc / kg, about 8.6×10 11 gc / kg, about 8.7×10 11 gc / kg, about 8.8×10 11 gc / kg, about 8.9×10 11 gc / kg, about 9.0×10 11 gc / kg, about 9.1×10 11 gc / kg, about 9.2×10 11 gc / kg, about 9.3×10 11 gc / kg, about 9.4×10 11 gc / kg, about 9.5×10 11 gc / kg, about 9.6×10 11gc / kg, about 9.7×10 11 gc / kg, about 9.8×10 11 gc / kg or about 9.9×10 11 gc / kg.
[0171] In some aspects, the dose is about 1.0×10 12 gc / kg, about 1.1×10 12 gc / kg, about 1.2×10 12 gc / kg, about 1.3×10 12 gc / kg, about 1.4×10 12 gc / kg, about 1.5×10 12 gc / kg, about 1.6×10 12 gc / kg, about 1.7×10 12 gc / kg, about 1.8×10 12 gc / kg, about 1.9×10 12 gc / kg, about 2.0×10 12 gc / kg, about 2.1×10 12 gc / kg, about 2.2×10 12 gc / kg, about 2.3×10 12 gc / kg, about 2.4×10 12 gc / kg, about 2.5×10 12 gc / kg, about 2.6×10 12 gc / kg, about 2.7×10 12 gc / kg, about 2.8×10 12 gc / kg, about 2.9×10 12 gc / kg, about 3.0×10 12 gc / kg, about 3.1×10 12 gc / kg, about 3.2×10 12 gc / kg, about 3.3×10 12 gc / kg, about 3.4×10 12 gc / kg, about 3.5×10 12 gc / kg, about 3.6×10 12 gc / kg, about 3.7×10 12 gc / kg, about 3.8×10 12 gc / kg, about 3.9×10 12 gc / kg, about 4.0×10 12 gc / kg, about 4.1×10 12 gc / kg, about 4.2×10 12 gc / kg, about 4.3×10 12gc / kg, about 4.4×10 12 gc / kg, about 4.5×10 12 gc / kg, about 4.6×10 12 gc / kg, about 4.7×10 12 gc / kg, about 4.8×10 12 gc / kg, about 4.9×10 12 gc / kg, about 5.0×10 12 gc / kg, about 5.1×10 12 gc / kg, about 5.2×10 12 gc / kg, about 5.3×10 12 gc / kg, about 5.4×10 12 gc / kg, about 5.5×10 12 gc / kg, about 5.6×10 12 gc / kg, about 5.7×10 12 gc / kg, about 5.8×10 12 gc / kg, about 5.9×10 12 gc / kg, about 6.0×10 12 gc / kg, about 6.1×10 12 gc / kg, about 6.2×10 12 gc / kg, about 6.3×10 12 gc / kg, about 6.4×10 12 gc / kg, about 6.5×10 12 gc / kg, about 6.6×10 12 gc / kg, about 6.7×10 12 gc / kg, about 6.8×10 12 gc / kg, about 6.9×10 12 gc / kg, about 7.0×10 12 gc / kg, about 7.1×10 12 gc / kg, about 7.2×10 12 gc / kg, about 7.3×10 12 gc / kg, about 7.4×10 12 gc / kg, about 7.5×10 12 gc / kg, about 7.6×10 12 gc / kg, about 7.7×10 12 gc / kg, about 7.8×10 12 gc / kg, about 7.9×10 12 gc / kg, about 8.0×10 12 gc / kg, about 8.1×10 12 gc / kg, about 8.2×1012 gc / kg, about 8.3×10 12 gc / kg, about 8.4×10 12 gc / kg, about 8.5×10 12 gc / kg, about 8.6×10 12 gc / kg, about 8.7×10 12 gc / kg, about 8.8×10 12 gc / kg, about 8.9×10 12 gc / kg, about 9.0×10 12 gc / kg, about 9.1×10 12 gc / kg, about 9.2×10 12 gc / kg, about 9.3×10 12 gc / kg, about 9.4×10 12 gc / kg, about 9.5×10 12 gc / kg, about 9.6×10 12 gc / kg, about 9.7×10 12 gc / kg, about 9.8×10 12 gc / kg or about 9.9×10 12 gc / kg.
[0172] In some aspects, the dose is about 1.0×10 11 gc / kg, about 1.1×10 11 gc / kg, about 1.2×10 11 gc / kg, about 1.3×10 11 gc / kg, about 1.4×10 11 gc / kg, about 1.5×10 11 gc / kg, about 1.6×10 11 gc / kg, about 1.7×10 11 gc / kg, about 1.8×10 11 gc / kg, about 1.9×10 11 gc / kg, about 2.0×10 11 gc / kg, about 2.1×10 11 gc / kg, about 2.2×10 11 gc / kg, about 2.3×10 11 gc / kg, about 2.4×10 11 gc / kg, about 2.5×10 11 gc / kg, about 2.6×10 11 gc / kg, about 2.7×10 11 gc / kg or about 2.8×10 11 gc / kg.
[0173] In some aspects, the dose is about 5.0×10 11 gc / kg, about 5.1×10 11 gc / kg, about 5.2×10 11 gc / kg, about 5.3×10 11 gc / kg, about 5.4×10 11 gc / kg, about 5.5×10 11 gc / kg, about 5.6×10 11 gc / kg, about 5.7×10 11 gc / kg, about 5.8×10 11 gc / kg, about 5.9×10 11 gc / kg, about 6.0×10 11 gc / kg, about 6.1×10 11 gc / kg, about 6.2×10 11 gc / kg, about 6.3×10 11 gc / kg, about 6.4×10 11 gc / kg, about 6.5×10 11 gc / kg or about 6.6×10 11 gc / kg.
[0174] In some aspects, the dose is about 1.0×10 12 gc / kg, about 1.1×10 12 gc / kg, about 1.2×10 12 gc / kg, about 1.3×10 12 gc / kg, about 1.4×10 12 gc / kg, about 1.5×10 12 gc / kg, about 1.6×10 12 gc / kg, about 1.7×10 12 gc / kg, about 1.8×10 12 gc / kg, about 1.9×10 12 gc / kg or about 2.0×10 12 gc / kg.
[0175] In some aspects, the dose is about 1.8×10 11 gc / kg. In some aspects, the dose is about 5.6×10 11 gc / kg. In some aspects, the dose is about 5.7×10 11 gc / kg. In some aspects, the dose is about 1.8×10 12 gc / kg.
[0176] In some aspects, the dose is measured by quantitative polymerase chain reaction (qPCR) titer. In some aspects, the dose is measured by droplet digital polymerase chain reaction (ddPCR) titer.
[0177] In some aspects, the therapeutically effective dose can be tailored for each AAV capsid serotype. In some aspects, the therapeutically effective dose is tailored based on the differences in cardiac tropism of different AAV capsid serotypes.
[0178] In some aspects, a single dose of the AAV vector is administered to the subject. In some aspects, the subject is also administered a second, third, fourth, or fifth dose of the AAV vector. In some aspects, the second and subsequent administrations of the AAV vector can be different doses from the first dose.
[0179] In some aspects, the subject is also administered prednisone concurrently with the administration of the AAV vector.
[0180] In some aspects, prednisone is administered as follows:
[0181] Administer at a dose of 40 mg once daily 24 hours before AAV viral vector administration;
[0182] Administer at a dose of 40 mg once daily from week 1 to week 8 after AAV viral vector administration;
[0183] Administered once daily at a dose of 30 mg in the 9th week after AAV viral vector administration;
[0184] Administered once daily at a dose of 20 mg in the 10th week after AAV viral vector administration;
[0185] Administered once daily at a dose of 10 mg in week 11 after AAV viral vector administration;
[0186] Administered once daily at a dose of 5 mg in week 12 after AAV viral vector administration;
[0187] Administered once daily at a dose of 2.5 mg in week 13 after AAV viral vector administration; and
[0188] The AAV vector was administered at a dose of 2.5 mg every other day at week 14 after administration.
[0189] In some aspects, the AAV vector is delivered directly into the myocardium by epicardial injection, followed by mini-incision surgery, intracoronary injection, intramyocardial injection, subepicardial or epicardial injection, or other types of injections that can be used in the heart.
[0190] Additional routes of administration may also include local administration of the vector under direct visualization, such as surface cortical administration or other non-stereotactic administration. The vector may be delivered intrathecally, intracerebroventricularly or by intravenous injection.
[0191] The target cells of the vector of the invention are cells of the myocardium of a subject suffering from a cardiomyopathy associated with Friedreich's ataxia. Preferably, the subject is a human, an adult or a child.
[0192] However, the present invention also encompasses delivery of the vector to a biological model of the disease. In this case, the biological model can be any mammal at any stage of development at the time of delivery, such as an embryo, fetus, infant, adolescent or adult. In addition, the target cardiomyocytes can be from essentially any source, in particular any cell derived from hiPS from FRDA patients, non-human primates and rodents (mice, rats, rabbits, hamsters), carnivores (cats, dogs) and artiodactyls (cows, pigs, sheep, goats, horses) and any other non-human system (e.g., zebrafish model system).
[0193] As used herein, carriers can be formulated in any suitable vehicle for delivery. For example, they can be placed in a pharmaceutically acceptable suspension, solution or emulsion. Suitable media include saline and liposome preparations. More specifically, pharmaceutically acceptable carriers may include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions or suspensions, including saline and buffered media. Intravenous vehicles include fluid and nutrient supplements, electrolyte supplements (such as those based on Ringer's dextrose), etc.
[0194] Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, and inert gases, among others.
[0195] Colloidal dispersion systems can also be used for targeted gene delivery. Colloidal dispersion systems include macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
[0196] In some aspects, the invention relates to a vector comprising a FXN encoding nucleic acid for treating or preventing cardiomyopathy associated with Friedreich's ataxia in a subject, wherein the AAV vector is delivered to a subject in need thereof, and wherein FXN is expressed by the transduced cells at therapeutically effective levels.
[0197] In a specific embodiment, the invention relates to a vector comprising a FXN encoding nucleic acid for use in reversing symptoms of cardiomyopathy associated with Friedreich's ataxia in a subject in need thereof, wherein the AAV vector is delivered to the subject in need thereof, and wherein FXN is expressed by the transduced cells at therapeutically effective levels.
[0198] Non-viral vectors
[0199] In a specific embodiment, the vector used according to the present invention is a non-viral vector. Generally, the non-viral vector may be a plasmid comprising a nucleic acid sequence encoding the FXN gene or a variant thereof as described above.
[0200] Pharmaceutical composition
[0201] In some aspects, the invention relates to a pharmaceutical composition for preventing or treating cardiomyopathy associated with Friedreich's ataxia in a subject in need thereof, the pharmaceutical composition comprising a therapeutically effective amount of an AAV vector comprising a FXN encoding nucleic acid.
[0202] By "therapeutically effective amount" is meant an amount of an AAV vector of the invention sufficient to treat cardiomyopathy associated with Friedreich's ataxia at a reasonable benefit / risk ratio applicable to any medical treatment.
[0203] It should be understood that the single dose or total daily dose of the compounds and compositions of the present invention will be determined by the attending physician within the scope of sound medical judgment. For any particular patient, the specific therapeutically effective dosage level will depend on a variety of factors, including the condition being treated and the severity of the condition; the activity of the specific compound employed; the specific composition employed; the patient's age, weight, general health, sex and diet; the administration time, route of administration and excretion rate of the specific compound employed; the duration of treatment; drugs used in combination or concomitantly with the specific polypeptide employed; and similar factors well known in the medical field. For example, it is entirely within the skill of the art to start using the compound at a dosage level lower than the dosage level required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. However, the daily dosage of the product can vary widely per adult per day. The therapeutically effective amount of the vector according to the present invention that should be administered and the dosage of the pathological condition treated with the virus or non-viral particles and / or pharmaceutical composition of the present invention will depend on a variety of factors, including the age and condition of the patient, the severity of the disorder or condition, the method and frequency of administration, and the specific peptide to be used.
[0204] The presentation of a pharmaceutical composition containing an AAV vector according to the invention may be in any form suitable for the chosen mode of administration (eg, for intraventricular, intramyocardial, intracoronary or intravenous administration).
[0205] In the pharmaceutical compositions of the present invention for intramuscular, intravenous, intramyocardial, intracoronary or intraventricular administration, the active ingredient (alone or in combination with another active ingredient) can be administered to animals and humans as a mixture with conventional pharmaceutical supports in a unit administration form.
[0206] Preferably, the pharmaceutical composition contains a pharmaceutically acceptable vehicle for a formulation capable of being injected. These may in particular be isotonic sterile saline solutions (mono- or disodium phosphate, sodium chloride, potassium chloride, calcium chloride or magnesium chloride, etc. or mixtures of such salts) or dried, especially lyophilized, compositions which, after adding, as appropriate, for example, sterile water or physiological saline, allow the constitution of injectable solutions.
[0207] Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid. The composition must be stable under the conditions of manufacture and storage and must be preserved in storage against the contaminating action of microorganisms such as bacteria and fungi.
[0208] Solutions containing the compounds of the invention in the form of free alkali or pharmacologically acceptable salts can be prepared in water suitably mixed with surfactants such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycol and mixtures thereof and in oils. Under common storage and use conditions, these preparations contain preservatives to prevent the growth of microorganisms.
[0209] The AAV vector according to the present invention can be formulated into a composition in neutral or salt form. Pharmaceutically acceptable salts include acid addition salts (formed with free amino groups of proteins), and pharmaceutically acceptable salts are formed with inorganic acids such as hydrochloric acid or phosphoric acid or organic acids such as acetic acid, oxalic acid, tartaric acid, mandelic acid, etc. Salts formed with free carboxyl groups can also be derived from inorganic bases such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide or ferric hydroxide and organic bases such as isopropylamine, trimethylamine, histidine, procaine, etc.
[0210] The carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol and liquid polyethylene glycol, etc.), suitable mixtures thereof and vegetable oils. Suitable fluidity can be maintained, for example, by using coatings such as lecithin, by maintaining the desired particle size in the case of dispersions, and by using a surfactant. Preventing the action of microorganisms can be achieved by various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc.). In many cases, it is preferred to include isotonic agents, for example, sugar or sodium chloride. The absorption of the injectable composition can be extended by using an agent that delays absorption (e.g., aluminum monostearate and gelatin) in the composition.
[0211] Sterile injectable solutions are prepared by incorporating the active polypeptide in the desired amount in an appropriate solvent, as necessary, along with several other ingredients listed above, followed by filter sterilization. Typically, dispersions are prepared by incorporating a variety of sterilized active ingredients into a sterile vehicle containing an alkaline dispersion medium and the desired other ingredients from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, preferred methods of preparation are vacuum drying techniques and freeze drying techniques, thereby producing a powder of the active ingredient plus any additional desired ingredients from a previously sterile filtered solution thereof.
[0212] After formulation, the solution will be administered in a manner compatible with the dosage formulation and in a therapeutically effective amount. The formulation is readily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like may also be employed.
[0213] Multiple doses may also be administered.
[0214] In some aspects, the invention relates to a method for treating or preventing a disease associated with Friedreich's ataxia deficiency in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a vector comprising a nucleic acid encoding Friedreich's ataxia protein.
[0215] Example
[0216] The present invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted as limiting the scope of the present invention in any way.
[0217] Example 1: Preclinical Evaluation of Friedreich's Ataxia Protein AAV Vector Therapy
[0218] In order to make in vivo adeno-associated virus (AAV) gene therapy successful, it is critical to identify the minimum effective clinical dose, thereby setting treatment targets for human clinical trials. Friedreich's ataxia (FA) is a life-threatening disease with no current treatments that modify the condition, characterized by neurological and cardiac dysfunction. Most FA patients are homozygous for the GAA trinucleotide expansion within the first intron of the Friedreich's ataxia protein (FXN) gene, which causes transcriptional silencing, resulting in reduced levels of FXN mRNA and protein. Although progressive neurological diseases limit activity, cardiomyopathy is the cause of death in nearly two-thirds of individuals. According to previous studies in experimental animals, it is well known that adeno-associated virus serotype rh.10 (AAVrh.10hFXN) expressing human FXN effectively treats cardiac manifestations of the disease in mouse FA models, but the therapeutic window is narrow, with high doses of hFXN transgenes associated with toxicity. Therefore, it is critical to determine the dose that will effectively treat the cardiac manifestations of FA in subjects.
[0219] It is well known that FA heterozygotes with one normal FXN allele have no clinical manifestations of FA. Therefore, the level of FXN required to convert a FA homozygous heart to a heterozygous heart was estimated. Analysis of the mean FXN levels in autopsy samples of the hearts of 5 individuals confirmed that the normal level of FXN in the human heart is 59±5ng / mg protein. It is estimated that the average cardiac Friedreich's ataxia protein level in FA homozygotes is about 9.4ng / mg. Further, it is well known that FA heterozygotes have 30%-80% of the normal level of FXN (19-50ng / mg Friedreich's ataxia protein). It is estimated that in order to be effective, AAV vectors need to provide Friedreich's ataxia protein expression of >9ng / mg. For effective therapy (heterozygote 19-50ng / mg - FA homozygote about 10ng / mg = 9-40ng / mg).
[0220] Mouse dosing studies
[0221] The MCK (creatine kinase- / -fxn-deficient) mouse is a model of severe heart disease that completely lacks the murine FXN protein in cardiac and skeletal muscle. MCK mice have progressive disease progression, with untreated animals dying at 11 weeks.
[0222] To determine the dose of AAVrh.10hFXN required to produce >8.3 ng / mg in the heart, 1.8 × 10 11 , 5.7×10 11 or 1.8 × 10 12AAVrh.10hFXN was administered intravenously to 7-week-old MCK mice (n=20 / dose; 10 females, 10 males) at gc / kg doses (determined by qPCR). These doses were selected because they were significantly lower than those previously shown to be toxic (14-fold to 140-fold). After administration, hFXN protein levels in cardiac tissue, body weight, echocardiography, cardiac function, and mortality were evaluated.
[0223] Expression of hFXN in mouse heart tissue
[0224] Evaluation of total hFXN protein in cardiac tissue of MCK mice after administration of AAVrh.10hFXN showed a dose-dependent increase in cardiac hFXN expression with increasing doses of intravenous AAVrh.10hFXN. Figure 1A As shown, 1.8 × 10 11 gc / kg, 5.7×10 11 gc / kg and 18×10 12 The gc / kg dose of AAVrh.10hFXN vector resulted in cardiac hFXN protein levels of 0.51 ng / mg, 6.07 ng / mg, and 33.71 ng / mg, respectively. To determine if the cardiac levels observed in MCK mice were within the “therapeutic” range, these cardiac hFXN levels were summed with the expected endogenous FXN levels in FA patients as described above. Figure 1B As shown, at 5.7×10 11 and 1.8×10 12 gc / kg, when added to endogenous levels, the increase in FXN levels reached 26% and 73% of normal human heart FXN levels, respectively, and at 1.8×10 12 gc / kg dose was within the heterozygous range.
[0225] Effect of intravenous administration on mouse body weight
[0226] Three doses of AAVrh.10hFXN (1.8×10 11 gc / kg, 5.7×10 11 gc / kg and 1.8×10 12 The body weights of MCK mice were monitored after 4 h (gc / kg) and compared with those of mice administered PBS as a control. Figure 2A Shown are body weights of male mice administered three doses of vehicle compared to PBS. Figure 2B Body weights of female mice administered three doses of vehicle compared to PBS controls are shown. 12Significant differences were observed between the gc / kg AAVrh.10FXN cohorts (males and females combined; repeated measures ANOVA with effect of time) (p<0.001).
[0227] Dose enhancement studies
[0228] To determine whether higher doses and higher levels of Friedreich's ataxia protein expression conferred additional benefit, we administered AAVrh.10FXN intravenously to 7-week-old MCK mice in increasing doses in half-log increments: vehicle (0 gc / kg), 1.8 × 10 11 gc / kg, 5.7×10 11 gc / kg, 1.8×10 12 gc / kg, 5.7×10 12 gc / kg(3.3X),1.8×10 13 gc / kg(10X) and 5.7×10 13 gc / kg(33X)( Fig. 8A ). Reference initial dose targeting heterozygous cardiac FXN levels (1.8 × 10 12 gc / kg), these doses are referred to as 3.3X, 10X, and 33X) dose cohorts. After vehicle administration, health and behavioral assessments, echocardiograms, and cardiac and hepatic human FXN levels ( Figure 8B and Figure 8C Human cardiac FXN levels in all higher dose cohorts exceeded the target based on non-FA human hearts, rising to 20,800 ± 3,200 ng / mg protein in the 33X dose cohort ( Figure 8C ).
[0229] Heart function assessed by echocardiography
[0230] Echocardiography was used to assess the 12 Cardiac function of mice treated with gc / kg dose of AAVrh.10hFXN was altered and compared with that of untreated WT MCK mice and MCK mice mock-treated with PBS. Figure 3 A series of echocardiography images comparing three treatments are shown. The echocardiography images of the parasternal short axis section of the left ventricle were taken one week before use, two weeks after use, and 4 weeks after use. The lateral wall and septal wall of the left ventricle and their relative positioning during contraction and diastole were evaluated using images. Untreated MCK mice that were not used PBS simulation control survived to the four-week time point.
[0231] Cardiac ejection fraction and fractional shortening were measured during the experiment. Figure 4A-B shows the ejection fraction and shortening fraction of mice in the three treatments, respectively. Compared with PBS control, the mice treated with 1.8×10 12 The gc / kg dose improved ejection fraction and fractional shortening (p<0.05, comparing both).
[0232] The results of echocardiographic assessment showed that the 12 There was a significant dose-dependent increase in ejection fraction at week 11, from 18.9±4.5% in untreated controls to 31.9±2.9% in the reference dose cohort, and at 10X (1.8×10 13 gc / kg) dose cohort increased to 54.5±9.8%. 13 In conclusion, in the MCK mouse model of Friedreich's ataxia, AAV-mediated expression of Friedreich's ataxia protein above normal physiological levels resulted in significant survival and cardiac benefits, but was toxic at high doses.
[0233] Survival rate
[0234] The survival of mice administered three doses of AAVrh.10hFXN was assessed and compared to mock-treated mice administered PBS. Survival curves were generated to compare the percentage of mice alive over time after each treatment. The survival curves between the PBS control-treated cohort and the AAVrh.10hFXN dose cohort were compared using the log-rank (Mantel-Cox) test (Kaplan-Meier). Figure 5 As shown, at 5.7×10 11 A small but significant improvement in mortality was observed at the minimum effective dose of 1.8×10 12 The gc / kg significantly effective dose mediated a 21.5% improvement in mortality (p<0.001 compared to untreated controls).
[0235] Survival rates increased from a median of 87.5 days in the reference dose (1.8×1012 gc / kg) to a median of 5.7×10 12 gc / kg) for 119 days, at 10X (1.8×10 13 gc / kg) cohort was stable at 128 days. 13 gc / kg), survival was affected to varying degrees, with some animals surviving more than 200 days, but some dying earlier than those in the 10X cohort, which may represent toxicity at this dose.
[0236] in conclusion
[0237] In MCK mice, at 5.7 × 10 11 A trend toward a slight improvement in survival was observed at 1.8 × 10 gc / kg (minimum effective dose); this dose yielded 26% of normal human endogenous levels (when combined with the 16% residual level in FA subjects) and showed a 4% improvement in mortality. 12 gc / kg; this dose produced 73% of normal human endogenous levels in MCK mice (when combined with 16% residual levels in FA subjects) and resulted in beneficial results with significantly improved ejection fraction and fractional shortening compared to untreated MCK mice. These data identify a minimal and significantly effective dose with clinically relevant potential for treating cardiac manifestations of Friedreich's ataxia.
[0238] Toxicology studies in mice
[0239] Seven-week-old WT C57Bl / 6N mice were administered 1.2×10 12 , 3.7E×10 12 and 1.2×10 13 gc / kg LX2006 (AAVrh.10hFXN, an AAV vector encoding Friedreich's ataxia protein) was administered for 1 and 3 months and 5.6×10 11 , 1.8×10 12 and 5.6×10 12 gc / kg LX2006 was continued for 10 months to evaluate safety and toxicity.
[0240] Animals in the 1-month and 3-month cohorts survived to their planned termination periods, whereas animals in the 10-month cohort had weight loss in both time periods, necessitating early euthanasia. 12 gc / kg 4 / 12 males in the 10-month cohort, with the first time point being approximately 1.5 months (6 weeks). In the 10-month cohort, early mortality was attributed to hepatotoxicity. Although human Friedreich's ataxia protein (hFXN) levels were not determined in these mice, based on similar dose groups from the 1-month cohort (3.7 × 10 12 gc / kg, high levels of hepatic hFXN were found and may lead to toxicity. 12 gc / kg) and high dose (1.2×10 13 A series of less severe (but still adverse) liver findings were observed at 1 and 3 month time points in 1 gc / kg) males, with no adverse effects in females up to 3 months post-dosing.
[0241] The second weight loss time point that led to early euthanasia in the 10-month cohort occurred at 7 months (30 weeks) after dosing. 12 gc / kg) group and the rest of the animals in the medium dose (1.8×10 12 6 / 12 female mice in the 5.6×10 gc / kg) group had minimal to moderate liver changes similar to those in the planned 3-month cohort. 12 In the gc / kg group, clinical pathological changes were limited to elevations in aspartate aminotransferase (AST) and creatine kinase (CK). By this time point, the high hepatic hFXN levels observed over 1 month had decreased, while cardiac hFXN levels had increased, resulting in a 5.6 × 10 12 Levels in the gc / kg group were comparable. The reduction in cardiac succinate dehydrogenase (SDH) histochemistry scores in male mice at this dose level (88% of male control values) supports the hypothesis that hepatic and possibly cardiac Friedreich's ataxia levels may contribute to the reduced body weight of mice euthanized at 7 months.
[0242] At the planned 10-month autopsy, the only adverse finding related to treatment was hepatocellular carcinoma (HCC), which was present in 5.6 × 10 11 gc / kg was observed in 1 / 6 males and in 1.8×10 12 gc / kg was observed in 3 / 6 males. Although this finding is considered unfavorable in the context of this study, a large amount of available data suggests that HCC observed in mice after AAV treatment is unlikely to translate into a risk to humans, as this has not been observed in higher species or humans (FDA, Toxicity Risks of Adeno-associated Virus Vectors for Gene Therapy (GT) "02-03, September 2021). Therefore, the likelihood that clinical subjects are at risk of developing HCC after AAVrh.10hFXN treatment is extremely low.
[0243] Ten months after treatment, the lowest dose level was 5.6 × 10 11 gc / kg, with the exception of tracheobronchial lymph node follicular hyperplasia (indicative of an immune response that is not considered adverse) and HCC in one male mouse, there were no treatment-related clinical signs, weight changes, hematology or clinical chemistry findings, including changes in serum troponin, and no histopathological findings. Similar observations of AAV-related hepatocellular tumors have not been observed in species other than mice (either animals in AAV preclinical studies or human subjects in AAV clinical trials) (FDA 2021), so the likelihood that clinical subjects are at risk for developing HCC after AAVrh.10hFXN treatment is extremely low.
[0244] There were no abnormalities in central nervous system (CNS) pathology (spinal cord and brain) in mice at all doses and all time points. No dorsal root ganglion (DRG) toxicity was observed at any dose in any animal.
[0245] IV administration of AAVrh.10hFXN to male and female C57Bl / 6 mice resulted in dose- and time-dependent toxicity that appeared to correlate with the level of hFXN expression in the liver and possibly the heart (based on 5.6 × 10 hFXN in male mice euthanized at weeks 6 and 30). 12 gc / kg dose level relative to control cardiac SDH histochemistry was reduced). 11 At the low dose of 1.8×10 gc / kg, there were no adverse findings throughout the study, but one male mouse developed HCC at necropsy at 10 months. 12 At the gc / kg dose level (the only other dose level at which males survived throughout the study), HCC was also observed in 3 / 6 male mice, suggesting that this was a treatment-related event. 11 The gc / kg dose level represents the lowest observed adverse effect level (LOAEL) in male mice and the no observed adverse effect level (NOAEL) in female mice. However, based on the lack of corresponding findings in other species, AAV-associated HCC in male mice is not expected to be relevant to humans. Although this finding is considered unfavorable in the context of this study, there are data suggesting that HCC observed in mice after AAV treatment is unlikely to translate into a risk to humans, and this has not been observed in higher species or humans (FDA 2021).
[0246] Nonhuman primate dosing studies
[0247] To determine the 1.8 × 10 12 To determine whether a significantly effective dose of gc / kg could achieve heterozygous levels in a large animal model, this dose was administered intravenously to African green nonhuman primates (NHPs) (n=10). Figure 6 A schematic diagram depicting the administration method and dose evaluation in NHPs is shown. After 12 weeks following administration of a significantly effective dose, levels in the heart were approximately 18 ng / mg, comparable to levels within the estimated range required to convert FA homozygotes to FA heterozygotes.
[0248] Two doses were evaluated in nonhuman primates, including the minimum effective dose determined in MCK mice (5.7 × 10 11 gc / kg and a significant effective dose (1.8×10 12gc / kg). Two doses of AAVrh.10 hFXN were administered intravenously to African green nonhuman primates (4 primates per dose; 2 / sex / dose) and compared with PBS administration (2 primates total; 1 / sex). After 12 weeks post-administration, samples from five regions of the heart (left / right ventricular wall, left / right atrium, and septum) were collected and examined for hFXN levels. Data from all five regions were combined for total heart tissue measurements.
[0249] Expression of hFXN in non-human primate cardiac tissue
[0250] Evaluation of total hFXN protein in NHP cardiac tissue after two doses of AAVrh.10hFXN showed a dose-dependent increase in cardiac hFXN expression. Heart samples from NHPs administered PBS had background levels of FXN due to cross-reactivity of the antibody. Fig. 7A As shown, 5.7×10 11 gc / kg and 1.8×10 12 gc / kg of AAVrh.10hFXN was associated with cardiac hFXN protein levels of 49 ng / mg and 63.1 ng / mg, respectively. The hFXN protein level in the PBS control group was 45.2 ng / mg.
[0251] To determine if the cardiac levels observed in NHPs were within the “therapeutic” range, these hFXN levels were summed with the expected endogenous FXN levels described above. Figure 7B As shown, at 5.7×10 11 and 1.8×10 12 gc / kg, when added to endogenous levels, the increase in FXN levels reached 22% and 46% of normal human heart FXN levels, respectively, and at 1.8×10 12 gc / kg dose was within the heterozygous range.
[0252] in conclusion
[0253] In nonhuman primates, when combined with the 16% residual level in FA subjects, 5.7 × 10 11 and 1.8×10 12 Intravenous doses of 100 gc / kg produced 22% and 46% of normal endogenous levels, respectively.
[0254] The threshold for a “nontoxic” level was set by carefully determining the level of therapeutic FXN protein required in humans. Dose titration studies in two animal models (MCK mice and nonhuman primates) demonstrated that the dose of AAVrh.10hFXN (1.8 × 10 11 , 5.6-5.7×10 11 and 1.8×1012 gc / kg) has the potential to mediate meaningful improvements in FA disease progression. Together, these data identify a therapeutically effective dose with clinically relevant potential for treating the cardiac manifestations of Friedreich's ataxia.
[0255] Example 2: Evaluation of human doses for Friedreich's ataxia protein AAV vector therapy
[0256] A first-in-human (FIH), 52-week, dose-escalation, open-label study of LX2006 (a Friedreich's ataxia AAV vector of the present disclosure) will be conducted in participants with FA with evidence of cardiomyopathy, followed by a long-term follow-up (LTFU) portion of the study for all participants who received LX2006.
[0257] Increasing doses of LX2006 (1.8×10 11 , 5.6×10 11 gc / kg) to recruit two consecutive cohorts (N=5 adult FA participants in each cohort). All participants will stay in the hospital for two nights after dosing and will be discharged on the 3rd day. The first two participants in each cohort will live near the research center during the first 4 weeks. The next 3 participants (#3, 4 and 5) will stay near the research center for at least 2 weeks. There will be at least 4 weeks between participants in each cohort to obtain 4 weeks of safety data (including laboratory tests) from the previous participant. The available safety data of all previous participants will also determine the dosing of additional participants.
[0258] Duration of treatment will be a single administration of LX2006, administered as a slow intravenous (IV) infusion over 60 minutes at an appropriate dose based on the study cohort. Further, patients will be administered prophylactic prednisone to minimize host immune responses to AAV-based therapies. Participants will receive 40 mg once a day (QD) from Day -1 to Week 8. Tapering begins at Week 9 and continues through Week 14, but dose adjustments are made based on alanine transaminase (ALT) and aspartate transaminase (AST) values as described below. Take prednisone QD, with morning dosing recommended.
[0259] Safety and efficacy assessment
[0260] Since hFXN expression is a key determinant associated with safety and efficacy in FA disease, nonclinical studies provide a better understanding of which doses are associated with toxicity and which doses produce safe and effective FXN expression. In conclusion, it is expected that achieving approximately 30% of normal human myocardial FXN levels will provide clinically meaningful benefit in FA patients.
[0261] Main efficacy target
[0262] The effect of LX2006 on peak V02 will be assessed based on a cardiopulmonary exercise test (CPET) using arm ergometer. The change in peak VO2 at week 52 compared to pre-treatment baseline will be measured.
[0263] Secondary Objectives
[0264] To evaluate the effect of LX2006 on left ventricular mass index (LVMi) measured by cardiac MRI. Change from baseline in LVMi will be measured at Week 52. Change from baseline in LVMi will be measured at Weeks 12, 24, and 36 and annually during the 4 years of LTFU.
[0265] The aim is to evaluate the effect of LX2006 on peak VO2 based on CPET (using arm ergometer). The change from baseline in peak VO2 will be measured at weeks 12, 24, 36 and annually during the 4 years of LTFU, for a total of 5 years after dosing.
[0266] The aim is to measure global longitudinal strain based on cardiac magnetic resonance imaging (MRI). Changes from baseline in global longitudinal strain will be measured at Weeks 12, 36, 24, 36, and 52 and annually during the 4 years of LTFU for a total of 5 years after dosing.
[0267] Stroke volume is designed to be measured based on cardiac MRI. Change in stroke volume from baseline will be measured at Weeks 12, 24, 36, and 52 and annually during the 4 years of LTFU for a total of 5 years post-dosing.
[0268] Left ventricular ejection fraction (LVEF) is intended to be measured based on cardiac MRI. Changes from baseline in LVEF will be measured at weeks 12, 24, 36, and 52 and annually during the 4 years of LTFU, for a total of 5 years post-dosing.
[0269] Cardiac fibrosis is designed to be measured based on cardiac MRI. Changes from baseline in cardiac fibrosis will be measured at Weeks 12, 24, 36, and 52 and annually during the 4 years of LTFU, for a total of 5 years post-dosing.
[0270] Serum NTproBNP, hsTNT, and CK-MB levels will be measured. Changes from baseline in cardiac biomarkers will be measured at weeks 2, 12, 24, 36, and 52, and annually during the 4 years of LTFU, for a total of 5 years post-dosing.
[0271] The aim is to measure arrhythmias based on remote rhythm monitoring. The presence and severity of arrhythmias at weeks 12, 24, 36, and 52 and annually during the 4 years of LTFU, for a total of 5 years after dosing.
[0272] Fatigue is designed to be measured based on the Modified Fatigue Impact Scale (MFIS) and the Fatigue Severity Scale (FSS). The presence and severity of fatigue will be measured at Weeks 12, 24, 36, and 52, and annually during the 4 years of LTFU, for a total of 5 years after dosing.
[0273] Exertional symptoms are designed to be measured during CPET based on the modified Borg dyspnea, Borg Rating of Perceived Exhaustion (RPE), and Angina Scale. Changes from baseline in the modified Borg dyspnea, Borg RPE, and Angina Scale will be measured at Weeks 12, 24, 36, and 52, and annually during the 4 years of LTFU for a total of 5 years post-dosing.
[0274] Third level goal
[0275] To determine vector copy number (VCN) in cardiac biopsy. Change in vector copy from baseline will be measured at Week 12.
[0276] Echocardiography (ECHO) based cardiac parameters are designed to be measured, including but not limited to LVMi, LVEF, and global longitudinal strain. Changes from baseline in cardiac ECHO measurements will be measured at 1, 2, 4, 12, 24, 36, and 52 weeks and annually during the 4 years of LTFU, for a total of 5 years after dosing.
[0277] The aim is to measure 12-lead electrocardiogram (ECG) parameters, including but not limited to ST-T wave changes. Changes from baseline in the 12-lead ECG will be measured at Weeks 1, 2, 4, 12, 24, 36, and 52, and annually during the 4 years of LTFU, for a total of 5 years after dosing.
[0278] Symptoms are designed to be measured based on the Seattle Angina Questionnaire, Shortness of Breath-Daily Activities Score, Visual Edema Score, and ankle diameter. Changes from baseline in the Seattle Angina Questionnaire and Shortness of Breath-Daily Activities Score will be measured at Weeks 12, 24, 36, and 52, and annually during the 4 years of LTFU for a total of 5 years after dosing.
[0279] The aim is to evaluate the effect of LX2006 on other CPET measures, including but not limited to: 1. Minute ventilation to carbon dioxide production (VE / VCO2) slope; 2. End tidal CO2 partial pressure (PETCO2); 3. Duration of exercise during CPET; 4. VO2 at ventilatory threshold (VT); 5. Oxygen extraction efficiency slope (OUES). Changes from baseline in VE / VCO2 slope, PETCO2, duration of exercise, VO2 at VT, and OUES will be measured at weeks 12, 24, 36, and 52, and annually during the 4 years of LTFU, for a total of 5 years after dosing.
[0280] Exploratory goals
[0281] The aim is to explore cardiac extracellular volume (ECV). Changes from baseline in cardiac ECV will be measured based on cardiac MRI at weeks 12, 24, 36, and 52, and annually during the 4 years of LTFU, for a total of 5 years after dosing.
[0282] The aim is to explore the effect of LX2006 on FXN protein levels in buccal cells and PBMCs. Changes from baseline in FXN protein in buccal cells and PBMCs will be measured at weeks 4, 12, 24, 36, and 52.
[0283] The aim is to explore the effect of LX2006 on measures of FA, including but not limited to the Friedreich Ataxia Rating Scale (FARS), Friedreich Ataxia Rating Scale-Activities of Daily Living (FARS-ADL), Modified Friedreich Ataxia Rating Scale (mFARS), Scale for the Assessment and Rating of Ataxia (SARA). Changes from baseline in FARS, FARS-ADL, mFARS, SARA, and others will be measured at Weeks 12, 24, 36, and 52, and annually during the 4 years of LTFU, for a total of 5 years after dosing.
[0284] To explore vector shedding of LX2006, vector shedding will be measured in oral, urine, blood, and fecal samples at weeks 1, 2, 4, 12, 24, and 52 and annually during the 4 years of LTFU until 5 years after dosing.
[0285] Heart Biopsy:
[0286] Fluoroscopy and ultrasound will be used during cardiac biopsy performed by appropriately trained staff at the study center before starting gene therapy and 12 weeks after treatment. All subjects will undergo a physical examination to determine if there are any complications that put the participant at higher risk. The collected septum piece can be divided into approximately 8 pieces. Evaluations will include vector copy number, FXN protein, cardiomyocyte FXN staining (if available), and electron microscopy.
[0287] Details of tissue sampling will be provided in the cardiac biopsy manual. In addition, during the cardiac biopsy procedure, cardiac output will be measured using the Fick formula using a Swan-Ganz catheter. After the last patient in each cohort has a biopsy at week 12, all tissues will be analyzed together.
[0288] Heart ECHO:
[0289] All participants underwent cardiac ECHO at screening / baseline and at time points detailed in this disclosure, which included measurements of LVMi, LVEF, stroke volume, and strain.
[0290] Cardiac MRI:
[0291] All participants will have an MRI scan of the heart at screening / baseline and at time points detailed in this disclosure. In LTFU, a cardiac MRI scan will be performed on Day 1 (if not already performed during the Week 52 visit during dose escalation) and annually. Participants must be able to tolerate contrast agents (e.g., gadolinium) as described in Exclusion Criteria #13. Cardiac MRI assessments include measurements of LVMi, LVEF, stroke volume, strain, and fibrosis.
[0292] Heart rhythm monitoring:
[0293] Arrhythmias were measured based on remote heart rhythm monitoring. After an in-person visit, a patch was placed on the participant's chest and worn remotely for 7 consecutive days for centralized assessment.
[0294] Clinician-Reported Outcomes
[0295] Friedreich Ataxia Rating Scale (FARS) and mFARS
[0296] FARS is a clinician-reported outcome measure that consists of three subscales: an overall score for ataxia, a score for activities of daily living (ADL), and a neurological examination. The neurological examination is a tool developed to measure neurological function in individuals with FA. The full tool has 25 items with a maximum total score of 125. The five domains of FARS are bulbar function, upper limb coordination, lower limb coordination, peripheral nervous system, and upright stability. Each item is rated based on the subject's status during the examination.
[0297] The modified FARS (mFARS) is a subset of the neurological examination in the FARS scale. The mFARS score is derived from the neurological examination that has been completed in the FARS scale. The mFARS has four of the five domains assessed by FARS; it does not include the peripheral nervous system.
[0298] Scale for Assessment and Rating of Ataxia (SARA)
[0299] SARA is an 8-item performance scale that assesses gait, standing, sitting, speech disturbance, finger tracking, nose finger test, rapid alternating hand movements, and heel-shin glide. The total score can be 0 (indicating no ataxia) to 40 (indicating the most severe ataxia).
[0300] Patient-Reported Outcomes
[0301] Shortness of breath-daily activities score (SOBDA)
[0302] The SOBDA 13-item questionnaire is a daily questionnaire developed to quantify participants' perception of dyspnea related to daily activities and to assess changes over time. Participants will be asked to complete the SOBDA daily for 7 days prior to their in-person visit.
[0303] Seattle Angina Questionnaire (SAQ)
[0304] The SAQ is a widely used patient-reported outcome measure in patients with heart disease. The SAQ is a self-administered questionnaire and consists of 19 items. The questionnaire measures the following 5 health-related quality of life domains with a recall period of 4 weeks. These domains are: physical limitations (9 items), angina stability (1 item), angina frequency (2 items), treatment satisfaction (4 items), and illness perception (3 items). Items are scored on a 5-point or 6-point Likert scale.
[0305] Fatigue scale (FSS, MFIS)
[0306] The Fatigue Severity Scale (FISS) is a patient-reported scale that assesses the impact of fatigue. Nine items are responded to using a 7-point Likert scale with an approval or disapproval. The recall period for this tool is within the previous week. A visual analog fatigue scale at the end of the tool captures overall fatigue, with 0 representing the worst level of fatigue and 10 representing normal.
[0307] A modified form of the Fatigue Impact Scale (MFIS) assesses the impact of fatigue on physical, cognitive, and psychosocial functioning. This instrument contains 21 items and has a 4-week recall period.
[0308] Pittsburgh Sleep Quality Index (PSQI)
[0309] The PSQI is a 19-item patient-reported instrument that measures sleep quality and disturbance over the past 4 weeks. The 7 components of sleep quality are 1) sleep duration, 2) sleep disturbance, 3) sleep latency, 4) daytime dysfunction due to sleepiness, 5) sleep efficiency, 6) overall sleep quality, and 7) sleep medication use.
[0310] Short Form Health Survey (SF-36)
[0311] The SF-36 is a 36-item patient-reported instrument that measures health-related quality of life. It measures physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health.
[0312] Evaluations during CPET
[0313] Modified Borg Dyspnea Scale
[0314] The modified Borg Dyspnea Scale is a 10-point scale used to measure patient-reported dyspnea during CPET, with 10 representing maximal dyspnea and 0 representing no dyspnea at all.
[0315] Angina Scale
[0316] The Angina Pectoris Scale (4-point scale with verbal descriptors) was used to standardize participant-reported perceived chest pain during CPET.
[0317] Borg Rating of Perceived Exertion (Borg RPE)
[0318] The Borg scale is a tool used to measure an individual's perceived effort and strain during physical exertion. It is a 15-point scale with verbal descriptors that was used to standardize the perceived strain reported by participants during CPET.
[0319] Biomarker Assessment
[0320] Blood samples will be collected for cardiac biomarkers (e.g., FXN expression, serum N-terminal prohormone B-type natriuretic peptide [NTproBNP], hsTNT, creatine kinase (CK) and its MB isoenzyme [CK-MB]) that may inform this treatment approach. Samples will be collected according to the schedule described in the SoA and as detailed in the laboratory manual provided separately to the study center. Biomarker samples should be collected prior to CPET evaluation.
Claims
1. A method for treating or preventing cardiomyopathy associated with Friedreich's ataxia in a subject, the method comprising administering to the subject a therapeutically effective amount of an adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a Friedreich's ataxia protein (FXN) polypeptide or a fragment thereof, wherein the AAV vector comprises in the 5' to 3' direction: The first AAV ITR sequence; enhancer sequences; Promoter sequence; chimeric intron; The nucleic acid sequence encoding Friedreich's ataxia protein (FXN) polypeptide; polyA sequence; and The second ITR sequence, and The carrier is about 1.0×10 10 gc / kg to about 6.0×10 14 A dose in the range of gc / kg is administered intravenously to the subject.
2. A method for treating or preventing cardiomyopathy associated with Friedreich's ataxia in a subject, the method comprising administering to the subject a therapeutically effective amount of an adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a Friedreich's ataxia protein (FXN) polypeptide or a fragment thereof, wherein the AAV vector comprises the nucleic acid sequence shown in SEQ ID NO:9, wherein the vector is expressed at about 1.8×10 11 gc / kg or about 5.6×10 11 A dose of gc / kg was administered intravenously to the subject.
3. The method of any one of the preceding claims, wherein the nucleic acid sequence encoding the Friedreich's ataxia protein (FXN) polypeptide comprises the nucleic acid sequence shown in SEQ ID NO:
3.
4. The method of any one of the preceding claims, wherein the first ITR sequence comprises the nucleic acid sequence shown in SEQ ID NO:
1.
5. The method of any one of the preceding claims, wherein the second ITR sequence comprises the nucleic acid sequence shown in SEQ ID NO:
2.
6. The method of any one of the preceding claims, wherein the enhancer sequence comprises the nucleic acid sequence shown in SEQ ID NO:
5.
7. The method of any one of the preceding claims, wherein the promoter sequence comprises the nucleic acid sequence shown in SEQ ID NO:
6.
8. The method of any one of the preceding claims, wherein the polyA sequence comprises the nucleic acid sequence shown in SEQ ID NO:
8.
9. The method of any of the preceding claims, wherein the AAV vector comprises the nucleic acid sequence shown in SEQ ID NO:
9.
10. The method of any one of the preceding claims, wherein the AAV vector is packaged as an AAV viral vector comprising an AAV capsid protein.
11. The method of any of the preceding claims, wherein the AAV capsid protein is an AAV1 capsid protein, an AAV2 capsid protein, an AAV4 capsid protein, an AAV5 capsid protein, an AAV6 capsid protein, an AAV7 capsid protein, an AAV8 capsid protein, an AAV9 capsid protein, an AAV10 capsid protein, an AAV11 capsid protein, an AAV12 capsid protein, an AAV13 capsid protein, an AAVPHP.B capsid protein, an AAVrh74 capsid protein, or an AAVrh.10 capsid protein.
12. The method of claim 11, wherein the AAV capsid protein is an AAVrh10 capsid protein.
13. The method of any of the preceding claims, wherein the dose is about 1.8×10 11 gc / kg.
14. The method of any of the preceding claims, wherein the dose is about 5.6×10 11 gc / kg.
15. The method of any one of the preceding claims, wherein the subject is also administered prednisone.
16. The method of claim 15, wherein the prednisone is administered as follows: Administer at a dose of 40 mg once daily 24 hours before AAV viral vector administration; Administer at a dose of 40 mg once daily from week 1 to week 8 after AAV viral vector administration; Administered once daily at a dose of 30 mg in the 9th week after AAV viral vector administration; Administered once daily at a dose of 20 mg in the 10th week after AAV viral vector administration; Administered once daily at a dose of 10 mg in week 11 after AAV viral vector administration; Administered once daily at a dose of 5 mg in week 12 after AAV viral vector administration; Administered once daily at a dose of 2.5 mg in week 13 after AAV viral vector administration; and The AAV vector was administered at a dose of 2.5 mg every other day at week 14 after administration.
17. The method of any of the preceding claims, wherein the intravenous administration is performed over about 60 minutes.
18. The method of any of the preceding claims, wherein the subject experiences an increase in peak VO2 following AAV vector administration relative to a baseline prior to AAV vector administration.
19. The method of claim 18, wherein the peak VO2 in the subject is measured at about 12 weeks, about 24 weeks, about 36 weeks, about 52 weeks, about 18 months, about 2 years, about 3 years, about 4 years, and / or about 5 years after AAV vector administration.
20. The method of claim 18 or 19, wherein the peak VO2 is measured by cardiopulmonary exercise testing (CPET) using arm ergometer.
21. The method of any of the preceding claims, wherein the subject experiences a decrease in left ventricular mass index (LVMi) following AAV vector administration relative to a baseline prior to AAV vector administration.
22. The method of claim 21, wherein the LVMi reduction is measured at about 12 weeks, about 24 weeks, about 36 weeks, about 52 weeks, about 18 months, about 2 years, about 3 years, about 4 years and / or about 5 years after AAV vector administration.
23. The method of claim 21 or 22, wherein the reduction in LVMi is measured by cardiac MRI.
24. The method of any of the preceding claims, wherein the subject experiences one or more of the following following AAV vector administration relative to a baseline prior to AAV vector administration: a decrease in global longitudinal strain, an increase in stroke volume, an increase in left ventricular ejection fraction (LVEF), and a decrease or stabilization of cardiac fibrosis as measured by cardiac MRI.
25. The method of claim 24, wherein the measuring by cardiac MRI occurs at about 12 weeks, about 24 weeks, about 36 weeks, about 52 weeks, about 18 months, about 2 years, about 3 years, about 4 years, and / or about 5 years after administration of the AAV vector.
26. The method of any of the preceding claims, wherein the subject experiences a decrease in serum NTproBNP, hsTNT, and CK-MB levels following AAV vector administration relative to a baseline prior to AAV vector administration.
27. The method of any of the preceding claims, wherein the subject experiences a reduction in arrhythmias following AAV vector administration relative to a baseline prior to AAV vector administration.
28. The method of claim 27, wherein the arrhythmia is assessed by remote cardiac rhythm monitoring.
29. The method of any of the preceding claims, wherein the subject experiences reduced fatigue following AAV vector administration relative to a baseline prior to AAV vector administration as measured by the Modified Fatigue Impact Scale (MFIS) or the Fatigue Severity Scale (FSS).
30. The method of any of the preceding claims, wherein the subject experiences improvement in exertional symptoms (by arm ergometer during CPET) following AAV vector administration relative to a baseline prior to AAV vector administration, as measured by the modified Borg dyspnea, Borg Rating of Perceived Exhaustion (RPE), and Angina Scale using CPET.
31. The method of any of the preceding claims, wherein the subject experiences an increase in FXN expression levels following AAV vector administration relative to a baseline prior to AAV vector administration.
32. The method of claim 31, wherein the FXN level is myocardial FXN expression level.
33. The method of claim 32, wherein myocardial FXN expression is measured by cardiac biopsy.
34. The method of claim 31, wherein the subject experiences an increase in FXN expression levels of at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 150%, at least about 200%, at least about 300%, at least about 400%.
35. The method of any of the preceding claims, wherein the subject experiences an improvement or stabilization of the Friedreich Ataxia Rating Scale (FARS) or modified Friedreich Ataxia Rating Scale (mFARS) following AAV vector administration relative to a baseline prior to AAV vector administration.
36. The method of any of the preceding claims, wherein the subject experiences an improvement or stabilization of the Scale for Assessment and Rating of Ataxia (SARA) following AAV vector administration relative to a baseline prior to AAV vector administration.
37. The method of any of the preceding claims, wherein the subject experiences an improvement or stabilization in shortness of breath-daily activities score (SOBDA) following AAV vector administration relative to a baseline prior to AAV vector administration.
38. The method of any of the preceding claims, wherein the subject experiences an improvement or stabilization of the Seattle Angina Questionnaire (SAQ) following AAV vector administration relative to a baseline prior to AAV vector administration.
39. The method of claim 1, wherein the dose is about 1.0×10 10 gc / kg to about 6.0×10 12 gc / kg.
40. The method of claim 1, wherein the dose is about 6.0×10 12 gc / kg to about 1.0×10 14 gc / kg.
Citation Information
Patent Citations
DNA constructs for retrovirus packaging cell lines
US4861719A
AAV transduction vectors
US5139941A
Production of recombinant adeno-associated virus vectors
US5173414A
Retroviral packaging cell lines and process of using same
US5278056A
Adenoviral vectors for gene therapy containing deletions in the adenoviral genome
US5882877A
